Plasma metabolomic and Growth Differentiation Factor-15 (GDF-15) in chronic heart failure with physical frailty

Konstantinos Prokopidis [a], Sima Jalali Farahani[b], Beyza Gulsah Altinpinar [a], Omid Khaiyat [b], Adam Burke [c], Amy Nortcliffe [a], Gregory Y.H. Lip[d], Rajiv Sankaranarayanan [e], Howbeer Muhamadali[c]*, Masoud Isanejad [a,e]*

[a] Department of Musculoskeletal Ageing and Science, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom

[b] School of Health and Sport Sciences, Liverpool Hope University, Liverpool, United Kingdom

[c] Centre for Metabolomics Research, Department of Biochemistry, Cell and Systems Biology, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, United Kingdom

[d] Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Science, University of Liverpool, Liverpool, United Kingdom

[e] Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom

[f]University Hospitals of Liverpool Group, University of Liverpool, United Kingdom

Corresponding author

Masoud Isanejad, e-mail: m.isanejad@liverpool.ac.uk, 6th West Derby Street, William Hendry Duncan Building University of Liverpool

Co-corresponding author

Howbeer Muhamadali, Howbeer.Muhamad-Ali@liverpool.ac.uk, 6th West Derby Street, Bio Science Building

Abstract

Background: chronic heart failure (HF) is a disease intertwined physical frailty are highly common. Investigating metabolic features and pathways associated with HF-Frailty can provide insight into molecular mechanisms, identify subphenotypes, and suggest potential therapeutic targets.

Methods: we collected data from total of 25 with chronic HF (mean age 67.9 ± 10.0 years) and 29 NonHF (mean age 67.8 ± 11.1 years). Physical frailty was assessed using low physical activity level in presence of low handgrip strength and/or 30-second chair stand test. Untargeted metabolomic profiling was performed. Plasma biomarkers including Growth Differentiation Factor (GDF)-15, were quantified. Statistical analyses were conducted via SPSS and MetaboAnalyst.

Results: The HF-Frail (n=25) compared to NonHF-NonFrail (n=18), had higher fat free mass (33.3 vs. 20.8 kg, P<0.01), but lower appendicular lean soft tissue to (22.8 vs. 20.2 P=0. 0.03), lower 6-miutes walking distance (386.4 vs. 501.3 meters, P<0.01), less 30-second chair stand repetitions (9.2 vs. 14.2, P<0.01), and weaker hand grip strength/BMI (1.05 vs. 1.41, P=0.035). HF-Frail compared to NonHF-NonFrail had significantly elevated plasma NT-proBNP (241.2 vs. 117.1 pg/ml, P=0.007), GDF-15 levels (1227.2 vs. 382.5 pg/ml, P<0.01). Agnostic principal component analysis revealed a distinct metabolic profile between HF-Frail compared to NonHF-NonFrail. HF-Frail showed elevated hexadecenoic acid, branched-chain amino acids, and glycolytic metabolites, with reduced glutamine and methionine and lower tryptophan and indole-3-acetamide, and higher tricarboxylic acid intermediates (e.g., citric acid, and glutaric acid-2oxo), compared to NonHF-NonFrail controls. Compared to HF-NonFrail, HF-Frail had lower galacturonic acid-1-phosphate, methionine, indole-3-acetamide, and energy metabolism intermediates (e.g., pyruvic acid, malic acid), but higher 2-hydroxy-glutaric acid. Similarly, pathway analysis revealed also enrichment of urea amino acid metabolism, fatty acids and BCAA degradations.

Conclusions: HF-Frail compared to NonHF-NonFrail showed exacerbated impaired energy metabolism, reduced ability to replenish excess tricarboxylic acids intermediates, alongside elevated inflammation and GDF-15, at least partly, indicate high systemic catabolism.

Keywords: heart failure, frailty, sarcopenia, metabolomics, biomarker

Introduction

Heart failure (HF) is a progressive clinical cardiometabolic syndrome, imposing a significant burden on healthcare systems, particularly among ageing populations [1]. There are several clinical risk factors for HF, such as ageing, high blood pressure, diabetes, obesity, atrial fibrillation, and coronary artery disease.

HF is associated with muscle wasting and sarcopenia, contributing to physical frailty [2]. Physical frailty, characterized by impaired muscle health (reduced strength and endurance), affects both HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF), and may contribute to lower quality of life and exercise tolerance, increasing mortality risk [2,3]. Although skeletal muscle function is significantly affected in HF and is integrally tied to cardiac metabolism, the mechanistic pathophysiological pathways are underexplored. In a meta-analysis, we showed that presence of low muscle strength was linked to increased severity of HF, as indicated by higher levels of B-type natriuretic peptide (BNP) and its N-terminal fragment (NT-proBNP) [4]. Also, impaired muscle health in HF may be due to systemic metabolic dysfunction rather than ageing alone [5-8], but few studies have addressed these specific mechanisms.

Metabolomics is promising tool to explore the molecular underpinnings of diseased states, including HF [9,10]. Previous studies employing metabolomics, has shown alterations in energy, amino acid, and lipid metabolism in HF, reflecting the systemic metabolic perturbations driven by cardiac dysfunction [10]. However, the application of metabolomics to investigate the compounded effects of HF and physical frailty remains limited. Recently, transforming growth factor (TGF)-β, and a group of pleiotropic cytokines, particularly activins and growth differentiation factors (GDF), such as GDF-15 and GDF-8 (or myostatin) have been implicated in various pathological conditions including cardiovascular disease[11] and muscle weakness[12]. In addition, factors such as follistatin-3 antagonists that bind activins/myostatin and prevent them from receptor signalling, may possess a key role in energy metabolism[13]. In this study, we performed plasma metabolomics obtained from HF and NonHF controls. First, we compared the total population of HF and NonHF, followed by HF with physical frailty (HF-Frail), patients with HF without physical

frailty (HF-NonFrail). Comparisons of plasma GDF-15, myostatin, activin A, and follistatin-3, among the groups was also performed, to explore associations.

Methods

STTOBE guideline for observational studies have ben followed.

Data Sharing Statement

Most of the data in the current study are presented in tables and figures. Metabolomics data coupled to deidentified metadata may be provided on reasonable request.

Study population

Patients with chronic HF were recruited by reviewing the medical records from Aintree Hospital at the Liverpool Hospital Foundation Trust from November 2023 until August 2024. All patients with HF have been diagnosed by cardiologists according to European Society Cardiology for HF guidelines [14]. The NTproBNP threshold was adapted from the National Institute for Health and Care Excellence, and echo ejection fraction estimation using the European Society Cardiology HF guidelines.

Participants had a clinical diagnosis of HF using left ventricular ejection fraction (LVEF%) for classification. Patients were included if they: i) had a body mass index (BMI) between 18 and 30 kg/m², ii) were age >50 years old, iii) were on optimal medical therapy for at least three months before study inclusion, iv) were able to provide consent and walk a minimum of 10 meters, with or without a walking aid, while v) NonHF adults were eligible if they were under control for hypertension or hypercholesterolemia without signs or history of a chronic conditions and were community-dwelling.

Participants were excluded if they: i) had a recent treatment (within three months) of antibiotics or probiotics, ii) had comorbidities such as chronic irritable bowel syndrome, kidney failure, or cancer at late stages, iii) were being treated with immunosuppressive medications, iv) had a presence of concurrent infection, and v) received cardiac resynchronization therapy within the past six months. NonHF participants were recruited from the general healthy population, self-reported no

chorionic diseases, Liverpool, UK. This study received sponsorship from the University of Liverpool and ethical approval from the London-Queen Square Research Ethics Committee (REC Reference: 23/PR/0050). The study was registered at Clinicaltrials.gov UoL001725. All participants provided written informed consent at enrolment.

Assessment of body composition, muscle strength, and physical function

The descriptive protocol is available in **Appendix 1**. Dual x-ray absorptiometry (GE Lunar Prodigy) was used to assess body composition. Appendicular lean soft tissue (ALST) was calculated by summing lean mass from arms and legs, excluding fat and bone, representing skeletal muscle mass.

Muscle strength was measured through handgrip strength (HGS) using a hand dynamometer (JAMAR hydraulic dynamometer), while knee extension strength was assessed by knee extension (Dynamo by VALD). The highest value of maximum three attempts was selected from the participants' dominant arm/leg. Physical function was assessed via 10-m walking speed, 3-m timed-up-and-go testing (TUG), 6-minute walking distance (6MWD), and 30-second chair stand test (30CST).

Physical Activity Assessment

Self-reported physical activity levels were assessed using the International Physical Activity Questionnaire (IPAQ) Short Form, and scores were calculated in accordance with the IPAQ scoring protocol (2005)[15]. Physical activity was quantified both continuously and categorically. For the continuous score, activity is expressed in metabolic equivalent (MET)-minutes per week. This is calculated by multiplying the number of minutes per day by the number of days per week and the assigned MET value for each activity domain: 3.3 for walking, 4.0 for moderate activity, and 8.0 for vigorous activity. The total physical activity score is obtained by summing all MET-minutes across the domains. For the categorical score, participants were classified into one of three levels of physical activity. Low: No reported activity, or activity levels insufficient to meet the criteria for the moderate or high categories. Moderate: Vigorous activity on ≥3 days for ≥20 minutes/day, or Moderate activity and/or walking on ≥5 days for ≥30 minutes/day, or Any combination of walking, moderate, or vigorous activity on≥5 days achieving at least 600 MET-minutes/week. High:

Vigorous activity on ≥3 days accumulating at least 1,500 MET-minutes/week, or a combination of activities on ≥7 days achieving at least 3,000 MET-minutes/week.

Physical frailty ascertainment

To ascertain physical frailty, we have adapted Fried criteria of frailty[16], for the low physical activity (IPAQ<2) as a component for physical frailty. Further, low HGS (men<27 kg as per the European Working Group on Sarcopenia in Older People (EWGSOP2) criteria and women<16 kg) [17]. And for the or low 30CST we utilised the guideline by Centres for Disease Control and Prevention (<11 repetitions). Notably, this physical frailty phenotype was significantly associated with lower quadriceps strength, slower walking speed, and longer 6-minute walking distance times, confirming global muscle weakness and reduced physical function in this group.

Quality of Life (SarQoL®)

The Sarcopenia Quality of Life **(**SarQol) questionnaire contains 22 questions grouped into 7 domains: physical and mental health, locomotion, body composition, functionality, activities of daily living, leisure activities, and fears[18]. Responses are recorded was self-reported, and scores were transformed to a total score ranging from 0 (lowest quality of life) to 100 (highest quality of life).

The SARC-F (Strength, Assistance with walking, Rise from a chair, Climb stairs, and Falls)

The SARC-F questionnaire comprises five components: strength, assistance with walking, rising from a chair, climbing stairs, and falls[19]. Each item is scored from 0 to 2, yielding a total score ranging from 0 to 10. A score of ≥4 suggests a high risk of sarcopenia and indicates the need for further diagnostic assessment. The SARC-F data was obtained via self-reported questionnaires.

Mini Nutritional Assessment (MNA)

The MNA questionnaire consists of 18 items covering anthropometric measurements, general health status, dietary habits, and self-perceived nutritional and health status[20]. The MNA data was obtained via self-reported questionnaires, and the total score ranges from 0 to 30, with scores ≥24 indicating normal nutritional status, 17–23.5 suggesting a risk of malnutrition, and <17 indicating malnutrition.

Sleep Quality

Participants self-reported their sleep quality with the Pittsburgh Sleep Quality Index (PSQI)[21], and Insomnia Severity Index (ISI)[22]. PSQI consists of 19 individual items grouped into seven components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. Each component is scored from 0 to 3, with higher scores indicating poorer sleep quality. The component scores are summed to yield a global score ranging from 0 to 21, with scores >5 indicating poor sleep quality. ISI comprises seven items assessing difficulty with sleep onset, sleep maintenance, and early morning awakening, as well as dissatisfaction with current sleep, interference with daily functioning, noticeability of impairment by others, and distress caused by the sleep problem. Each item is rated on a 5-point Likert scale (0–4), yielding a total score ranging from 0 to 28. Scores are interpreted as follows: 0–7, no clinically significant insomnia; 8–14, subthreshold insomnia; 15–21, moderate clinical insomnia; and 22–28, severe clinical insomnia.

Plasma procurement

Blood samples were collected in the morning after an overnight fast. Samples were centrifuged at 2000 g for 15-20 minutes at 4°C, aliquoted into two 2 mL microcentrifuge tubes, and stored at -80°C. Samples were then transferred to the Liverpool University Biobank Facility and were processed at the University of Liverpool for translational analysis.

Gas Chromatography-Mass spectrometry analysis

GC-MS was completed at the Centre for Metabolomics Research, University of Liverpool. Plasma samples were deproteinized in a single batch by adding 300 µl ice cold acetonitrile/methanol (1:1) to 100µl homogenised plasma spiked with deuterated internal standards, vortexed for 15 seconds and centrifuged at 30130 *g* for 15 minutes. Supernatant was transferred into microcentrifuge tubes (Eppendorf, Stevenage, UK) and lyophilised for 16 hours in a vacuum centrifuge (Savant SpeedVac SPD130DLX, Savant vapor trap RVT5105, (Fisher Scientific, Loughborough, UK). Pooled quality control (QC) and process blanks were prepared in tandem. Procedures for GC-MS analysis were adapted from the method presented by Dunn et al. [23] Lyophilised samples, QCs and blanks were derivatized in a two-step process, randomised and

analysed via autosampler injection with GC-MS. An Agilent 7250 GC-ToF-MS equipped with an HP-5ms (length 30 m, inner diameter 0.25 mm, film thickness 0.25 µm) capillary column (Agilent, Cheadle, UK) was utilised, with an oven temperature gradient of 70 °C, 4 min hold, 20 °C/min to 300 °C, 4 min hold, 300 °C transfer line temperature. MassHunter Acquisition software was set to automatically recalibrate the mass spectrometer following every four sample injections. Data were processed through spectral deconvolution, alignment, blank subtraction and retention index assignment. Peak annotation was performed using an in-house spectral library concatenated with purchased external libraries for untargeted discovery. Signal correction and quality assessment across the batch runs were carried out using pooled QC samples. The full experimental protocol available in **Appendix-Table 1.**

Metabolomic analysis

The imputed data were log-transformed for normalization before PCA agnostic clustering. We performed agnostic clustering using principal component analysis (PCA) in MetaboAnalyst 6.0 and examined the loading plots. The top three components were identified as the most significant contributors. Hierarchical clustering was performed based on correlation of metabolites and displayed heatmaps using MetaboAnalyst 6.0. Plasma metabolites among the groups were compared, using the peak intensity data (after log transformation and normalization), with independent t-test adjusted for the Benjamini-Hochberg method for pairwise comparison and ANOVA for the Fisher's Least Significant Difference (LSD) for 3-way comparisons.

Statistical analysis of clinical data

Demographic, clinical, laboratory, body composition and physical function data were compared across four groups HF-NonFrail; HF-Frail; NonHF-NonFrail; NonHF-Frail. Normality testing was employed through a Shapiro-Wilk Test. Distributions across groups was compared with the Kruskal-Wallis followed by the Mann Whitney U tests and independent t-tests were used for continuous variables during the assessment of outcomes in the two groups. A chi-squared test was used for categorical variables. Least Significant Difference (LSD) test was applied for multiple comparisons, and pairwise comparison was performed using and P values were reported to show the significantly for pairwise comparison, $P<0.05$ determined statistical significance,

using IBM SPSS version 31. Although we have established clinical phenotype for HFpEF and HFrEF, sensitivity or subgroup analysis could not yield value due to the relatively sample size.

Biomarker analysis

This study employed enzyme-linked immunosorbent assay (ELISA) to quantify GDF-15, myostatin, activin A, follistatin-3, tumour-necrosis-factor-α (TNF-α) [Thermo Fisher Scientific, Cat. No. KAC1751], interleukin-6 (IL-6) [Thermo Fisher Scientific, Cat. No. EH2IL6], C-reactive protein (CRP) [Thermo Fisher Scientific, Cat. No. KHA0031], glucose [Thermo Fisher Scientific, Cat. No. EIAGLUC], insulin [Thermo Fisher Scientific, Cat. No. BMS2003], and N-terminal pro-B-type natriuretic peptide (NT-proBNP) [Elabscience, Cat. No. E-EL-H6126], through commercially available human ELISA kits. Plasma samples were thawed on ice and diluted as required *as per* each biomarker's guidelines. Standards, controls, and samples were plated in duplicates on 96-well microplates precoated with capture antibodies. After incubation with biotin conjugate, and horseradish peroxidase-conjugated streptavidin, tetramethylbenzidine substrate was added. Absorbance was measured at 450 nm (IL-6 at 450 and 540 nm) using a microplate reader. Biomarker concentrations were determined by interpolating absorbance values against standard curves generated with known concentrations. Availability of data for these biomarkers in each group are shown in **Appendix-Table2**.

Results

Participant characteristics are presented in **Table 1**. Between the NonHF-NonFrail NonHF-Frail, there were no significant differences in sex distribution between non-frail and frail participants (21 [11 male/10 female] vs. 8 [3 male/5 female], P= 0.68). Mean age was comparable between groups (68.4 ± 12.3 vs. 66.5 ± 8.0 years, P= 0.76). BMI tended to be higher in the NonHF-Frail group (26.5 ± 3.5 kg/m²) compared to the NonHF-NonFrail group (25.1 ± 2.8 kg/m²), although this difference did not reach statistical significance (P= 0.14). Similarly, in the HF-Frail and HF-NonFrail cohort, sex distribution did not differ significantly between (7 [5 male/2 female] vs. 18 [14 male/4 female], P= 0.56). Mean age was similar between HF (68.4 ± 10.7 years) and HF-Frail (67.8 ± 10.1 years) groups (p = 0.89). BMI was also comparable between the two HF subgroups (31.3 ± 6.3 kg/m² vs. 30.4 ± 7.0 kg/m², P= 0.77).

The HF-Frail had the significantly lower self-reported moderate physical activity compared to HF-NonFrail (P<0.01) and NonHF-NonFrail (P = 0.04). The self-reported MNA score, and SarQoL was lower HF-Frail (P<0.01), compared to HF-NonFrail, and NonHF-NonFrail. HF-Frail had the highest BMI (P<0.01), followed by HF-NonFrail (P<0.01), and NonHF. Whereas HF-Frail had the lowest appendicular lean soft tissue/BMI (P=0.03), followed by HF-NonFrail and NonHF-NonFrail. The HF-Frail compared to NonHF-NonFrail had consistently lower physical function as indicated with longer 6-minute walking distance times (P<0.01), slower time Up and Go (P<0.01), lower repetitions in 30 Chair Stand Test (P<0.01), and weaker hand grip strength (P=0.035). HF-Frail compared to NonHF-NonFrail had elevated plasma levels for GDF-15 (P=0.03), NT-proBNP (P=0.01), and TNF-a (P=0.007).

Metabolic alterations in total HF compared to total NonHF

Figure 1A shows the principal component analysis (PCA), revealing separable clusters between the whole HF (HF-Frail+ HF-NonFrail) and Non-HF (NonHF-Frail+ NonHF-NonFrail) groups, with results presented in **Table S1**. In contrast, HFpEF and HFrEF had substantial overlap (**Figure 1B**). Several fatty acid related metabolites showed altered levels in total HF. Octadecadienoic acid (P< 0.001), octadecenoic acid methyl ester (P<0.001), and octadecenoic acid (P=0.037) were significantly higher in total. Also, tryptophan (P=0.002) and indole-3-acetamide (P=0.044) were higher in total Non-HF controls, while indole-3-hydroxy (P=0.0873) and indole-3-acetic acid (P= 0.3618) trended higher in HF. Several branched-chain amino acids (BCAAs) and related metabolites were elevated in HF, such as isoleucine (P<0.001), valine (P= 0.00598), and ornithine (P<0.001). Branched-chain fatty acid derivatives including isovaleric acid 2-oxo (P<0.001) and valeric acid 2-oxo (P= 0.0256) were also higher in HF. Regarding other amino acids, alanine (P<0.001) aspartic acid (P=0.00293), glutamic acid (P<0.001), cystine (P=0.00107), and histidine (P< 0.001) were significantly different between groups, with negative t-values indicating higher abundance in HF. In contrast, glutamine (P=0.719), asparagine (P<0.001), serine (P<0.001and methionine (P<0.001) showed strong group differences, with asparagine and serine elevated in total Non-HF controls and methionine reduced in HF. Several glycolysis and glycolysis-related metabolites were altered. Glucose 2-deoxy (P = 0.0232), glycerol (P<0.001), galactose (P<0.001), galacturonic acid (P< 0.001), and GalNAcol (P<0.001) were increased in HF, whereas fructose (P= 0.00115) and

gluconic acid-1,4-lactone (P<0.001) were reduced. Additionally, several metabolites showed significant differences, such as galactonic acid (P<0.001), and cystamine (P<0.001), between total HF and total Non-HF. Results of hierarchical clustering also confirms the separation between total HF and total NonHF as illustrated in **Figure 1C**.

We also performed mummichog analysis as illustrated in **Figure 1D** and data presented in **Table S2.** Metabolic pathway enrichment analysis identified several significantly affected pathways. The most prominent was beta-alanine metabolism (P Gamma= 0.0054), followed by urea cycle/amino group metabolism (P for Gamma= 0.0072), Lysine metabolism (P for Gamma= 0.0087), and Aspartate and asparagine metabolism (P for Gamma= 0.0172), and valine, leucine and isoleucine degradation (P for Gamma= 0.0305), indicating disruptions in branched-chain amino acid catabolism.

Metabolic alterations accounting for frailty phenotype in HF

In pairwise comparisons between HF-Frail and NonHF-NonFrail (**Table S3**), several metabolites were significantly higher in HF-Frail (P< 0.05), including cystamine (P<0.001), alanine (P<0.001), N-acetyl-L-aspartic acid (P<0.001), methionine (P<0.001), and galactose (P<0.001). Higher in controls were 2-piperidinecarboxylic acid (P<0.001) galactonic acid 1,4-lactone (P<0.001), octadecenoic acid methyl ester (P<0.001), N-carboxyglycine (P<0.001), and histidine (P<0.001). Differences were also observed in tricarboxylic acid (TCA) cycle intermediates such as malic acid (P<0.001), fumaric acid (P= 0.008) and Glutaric acid. 2-oxo (P<0.001). Branched-chain amino acids (BCAA) including isoleucine (P= 0.0174) and valine (P= 0.003) along with related catabolites, indicating broad coverage of core metabolic pathways in the observed alterations.

We screened metabolites in HF-Frail compared to those with HF but without frailty. The PCA results did not yield a significant model. Further, the supervised (PLS-DA) analyses were applied to select the variables responsible for the separation showed by models in **Figure 2**. The two first components showed the highest accuracy which were used as loading plots to generate the variable of Importance (VIP>1.0) contributing to the model. Differing VIPs between HF-Frail compared to their counterparts based on raw P-values included lower galacturonic acid-1-phosphate (P=

0.03), glutamic acid (P= 0.04), indole-3-acetamide (P< 0.01), methionine (P= 0.04), and phenylalanine P= 0.04). On the contrary, higher amounts of 2-hydroxy-glutaric acid were observed (P = 0.02) (**Table S4**).

Discussion

In this study, we have shown that low physical activity alongside with lower 30SCT (lower extremity strength) and low GS (upper extremity strength) can show a clinically meaningful distinction of frailty indices, and was associated with lower quality of life, and higher malnutrition. Levels of TNF-α, and GDF-15 was elevated in HF-Frail followed by HF-NonFrail, while the GDF-15 seems to have to most distinctive values when compared to NonHF-NonFrail (**Figure 3**). Further, metabolomics analysis revealed disruptions in HF-NonFrail and HF-Frail across the fatty acid-related metabolites, amino acid metabolism, and glycolytic pathways compared to NonHF controls, indicating impaired energy production and a catabolic state. These observations implicated new and interconnected metabolic links that may implicate pathobiological mechanism driving physical frailty and muscle weakness in HF.

Metabolic alterations in HF compared to NonHF controls

We initially investigated the plasma global metabolomic profiles distinguished the outcomes of interest total HF and total Non-HF and then followed this for HF-Frail and NonHF-NonFrail. Principal component analysis showed clear patterns of separation, which is notable in our chronic-HF phenotype (Figure 1). Elevated levels of hexadecenoic acid and BCAAs such as isoleucine and valine, along with their derivatives (isovaleric acid 2-oxo and valeric acid 2-oxo), were observed in HF. These findings align with prior research indicating that HF is associated with disrupted lipid and amino acid metabolism, likely due to impaired energy utilization and increased catabolic demands [24]. Elevation of BCAAs in HF may reflect impaired mitochondrial oxidative capacity via increased reactive oxygen species production and dysregulation of mitochondrial Ca^{2+} homeostasis [25,26], increased risk of insulin resistance [27], and disrupted cardiac energy substrate utilization, albeit a small amount of BCAAs is used in cardiac proteolysis [28]. Conversely, reductions in glutamine, asparagine, serine, and methionine in patients with HF suggest increased protein turnover and inefficient adenosine triphosphate (ATP) production to meet energy demands [29], for which, previous research has shown links to BNP, left ventricular ejection fraction and end-

diastolic volume index, and inferior vena cava diameter [30], potentiating risks of incident myocardial infarction [31]. In addition, the observed increases in glycolytic metabolites, such as glucose-2-deoxy, glycerol, galactose, galacturonic acid, and galNac-ol, and decreased fructose and gluconic acid, highlight altered carbohydrate metabolism in HF, which have been linked with cardiomyopathies and altered glucose transporter regulation (GLUT1 and GLUT4), that facilitate cardiac contractile function [32]. Overall, these changes may reflect compensatory mechanisms to sustain energy production in the failing heart, where oxidative phosphorylation is compromised. The elevation of glucose-related metabolites may also indicate insulin resistance, as supported by the higher HOMA-IR scores in patients with HF without frailty compared to NonHF counterparts.

Metabolic alterations in heart failure with frailty

Our findings regarding the HF-Frail phenotype revealed several differentially expressed metabolites, including galacturonic acid-1-phosphate, glutamic acid, indole-3-acetamide, methionine, phenylalanine, and 2-hydroxy-glutaric acid. These findings, although based on raw P-values, suggest that frailty in HF may amplify metabolic perturbations compared to patients with HF but without frailty. However, the elevation of amino acids such as glutamic acid and phenylalanine in HF-Frail yields controversial results regarding their link to frailty [33-36]. Regarding HF, there was a prognostic impact of higher phenylalanine pertaining to mortality and HF (re)hospitalization [37,38], while glutamic acid may reflect HF severity [39], that may be exacerbated by frailty. These findings align with our work on higher NT-proBNP levels and odds of HF hospitalization being associated with frailty in HF [40,41]. Furthermore, the higher levels of galacturonic acid-1-phosphate, a carbohydrate metabolite, may reflect altered glycosaminoglycan metabolism, potentially contributing to impaired tissue remodelling, considering that proteomics have demonstrated it as a top pathway associated with frailty [42]. It is worth noting that the HF-Frail cohort exhibited lower 30CST performance, reduced weekly moderate physical activity, and lower MET and MNA scores compared to patients with HF but without frailty.

These changes were accompanied by higher levels of glucose, TNF-α, and GDF-15, but lower levels of activin A compared to HF without frailty. Elevated GDF-15 is a

biomarker of inflammation and oxidative stress that has been previously linked to sarcopenia and frailty [43,44]. This suggests that GDF-15 may not only serve as a marker of HF hospitalization and mortality [45,46], or inflammation and malnutrition [47], but also of frailty and/or myopathy severity in HF. In addition, higher activin A has been linked to impaired cardiac remodelling [48], and myocardial damage [49] in humans and murine models, which contradict our results on the detrimental impact physical frailty may confer in HF. Our data showed that the ratio of activin A to follistatin-3 was lower in both the HF and HF-Frail groups compared to controls, suggesting that follistatin-3, as a natural antagonist, may sequester activin A more effectively in the HF-Frail phenotype.

The elevated levels of TNF-a in our study are in line with evidence on its link with frailty in cardiovascular diseases [50]. Overall, HF-Frail is characterized by altered galacturonic acid-1-phosphate, amino acids, glucose, TNF-α, and GDF-15, but lower activin A, reflecting increased metabolic stress, inflammation, and impaired tissue remodelling compared to HF counterparts without frailty. This observation suggests a multifactorial yet tightly interconnected relationship between heart failure (HF) and a muscle catabolic state. Preclinical models have demonstrated that insulin resistance and impaired mitochondrial respiratory capacity in skeletal muscle are associated with marked increases in GDF-15 expression and elevated plasma GDF-15 concentrations, indicating that skeletal muscle may be a primary source of increased circulating GDF-15 observed in middle-aged mice [51].

HF-Frail exhibited a broad range of metabolic alterations compared to NonHF controls without frailty. For instance, elevated amino acids (e.g., alanine, methionine, isoleucine, glutamic acid, ornithine, and cystine) and carbohydrate metabolites (e.g., galactose, galactonic acid, and glycerolaldopyranosid) suggest increased metabolic stress. Conversely, reduced levels of energy metabolism intermediates (e.g., pyruvic acid, malic acid, and 2-oxo-glutaric acid) indicate compromised mitochondrial energy production, a feature consistent with the systemic impact of frailty on energy homeostasis, which was also observed in the total HF vs. NonHF cohorts. The lower concentrations of tryptophan, histidine, serine, cysteine, and asparagine further highlight the catabolic state in HF-Frail, linking these to potentially accelerated muscle wasting and reduced production of serotonin, kynurenines, and NAD^+ as shown previously [52,53]. Thus, patients with HF and frailty may exhibit extensive

metabolic perturbations, including elevated amino acids and carbohydrate metabolites, and reduced energy intermediates compared to NonHF controls without frailty.

Clinical and research implications

The notable muscle weakness in HF-Frail was apparent at the similar age with NonHF and HF counterparts, suggesting that physical frailty can start at younger age in this population, which is an established risk factor for worsened prognosis in HF. The distinct metabolic profiles identified in this study could have significant implications for the management of HF, particularly in the context of physical frailty. The elevation of GDF-15 and TNF-α in HF-Frail highlights the role of inflammation, and oxidative stress in this population, suggesting that potential therapies (pharmacological and non-pharmacological) could be explored to mitigate frailty-related complications. Notably, GDF-15 has recently emerged as a therapeutic target in cancer-associated cachexia, a condition characterized by severe muscle and weight loss [54]. Additionally, the observed metabolic alterations, particularly in BCAAs, glycolytic metabolites, and the tryptophan-indole pathway [55], suggest potential therapeutic targets to improve energy metabolism and muscle health in HF-Frail.

For example, interventions aimed at enhancing mitochondrial function or optimizing amino acid metabolism could help alleviate frailty symptoms and improve functional outcomes [56,57]. Specifically, nutritional status, as indicated by lower MNA scores in HF with frailty, may be a critical factor, given its link to lower energy and protein intake, amplifying sarcopenia risk [58]. Additionally, the lower 30CST performance and physical activity levels in the HF-Frail group, marking further the need for tailored nutritional and exercise programs to improve physical function[59].

From a research perspective, the study highlights the importance of integrating frailty assessments into studies with participants who have HF to better understand its metabolic contributions. The lack of a significant model when screening metabolites between HF with and without frailty suggests that larger sample sizes or more sensitive analytical approaches may be needed in studies to fully elucidate frailty-specific metabolic signatures. Future studies could employ longitudinal designs to explore how these metabolic changes evolve over time and evaluate their prognostic impact on clinical outcomes such as hospitalization or mortality.

Study limitations

The relatively small sample size and cross-sectional nature precludes causal interpretations and to investigate the physical frailty bidirectionally to HF, particularly for frailty-specific analyses, where statistical significance was based on raw p-values rather than adjusted models. Additionally, the consideration of comorbidities and different prescribed medications may have an impact on metabolomic analyses. MSI level 2 annotations, not definitive metabolite identifications. Future work would be to run authentic standards to confirm the ones not already in CMR library, although hits in mummichog give extra confidence. Despite these constraints, the robust application of GC-MS in clinical and community-dwelling cohorts, provides further mechanistic insights into HF and physical frailty. These findings highlight the need for integrated approaches to manage HF and frailty, incorporating nutritional, exercise, and potentially pharmacological interventions to address metabolic and functional deficits.

Conclusions

This study provides novel insights into the metabolic alterations associated with HF and frailty, highlighting distinct profiles in lipid, amino acid, and carbohydrate metabolism. HF-Frail patients demonstrate exacerbated impaired energy metabolism, marked by reduced ability to replenish excess tricarboxylic acids intermediates, and altered amino acid and carbohydrate metabolism. Higher BCAAs and its catabolites, at least partly, indicate high systemic catabolism, alongside elevated inflammation and GDF-15, are markers of muscle wasting.

Conflicts of interest

Authors declare no conflict of interest.

Sources of funding

This study received funding from Dunhill Medical Trust (Dr Masoud Isanejad) and Liverpool Shared Research Facility (Dr Masoud Isanejad).

Acknowledgements

The authors would like to express their sincere gratitude to all participants of this study. We also gratefully acknowledge the invaluable contributions of the Liverpool University Biobank team, Dr. Viktoria Shaw, Mrs. Sue Holden, and Mrs. Katie

Bullock—for their support in biomarker analysis, as well as the processing and storage of samples and data used in this study.

References

1. Shahim B, Kapelios CJ, Savarese G, Lund LH. Global public health burden of heart failure: an updated review. *Cardiac failure review*. 2023;9:e11.

2. Von Haehling S, Ebner N, Dos Santos MR, Springer J, Anker SD. Muscle wasting and cachexia in heart failure: mechanisms and therapies. *Nature Reviews Cardiology*. 2017;14:323-341.

3. Prokopidis K, Isanejad M, Akpan A, Stefil M, Tajik B, Giannos P, Venturelli M, Sankaranarayanan R. Exercise and nutritional interventions on sarcopenia and frailty in heart failure: a narrative review of systematic reviews and meta-analyses. *ESC Heart Fail*. 2022. doi: 10.1002/ehf2.14052

4. Prokopidis K, Morwani-Mangnani J, McDowell G, Lip GYH, Venturelli M, Sankaranarayanan R, Isanejad M. Sarcopenia is linked to higher levels of B-type natriuretic peptide and its N-terminal fragment in heart failure: a systematic review and meta-analysis. *Eur Geriatr Med*. 2024. doi: 10.1007/s41999-024-00950-x

5. Cosiano MF, Tobin R, Mentz RJ, Greene SJ. Physical Functioning in Heart Failure With Preserved Ejection Fraction. *J Card Fail*. 2021;27:1002-1016. doi: 10.1016/j.cardfail.2021.04.013

6. Zamani P, Proto EA, Wilson N, Fazelinia H, Ding H, Spruce LA, Davila A, Jr., Hanff TC, Mazurek JA, Prenner SB, et al. Multimodality assessment of heart failure with preserved ejection fraction skeletal muscle reveals differences in the machinery of energy fuel metabolism. *ESC Heart Fail*. 2021;8:2698-2712. doi: 10.1002/ehf2.13329

7. Scandalis L, Kitzman DW, Nicklas BJ, Lyles M, Brubaker P, Nelson MB, Gordon M, Stone J, Bergstrom J, Neufer PD, et al. Skeletal Muscle Mitochondrial Respiration and Exercise Intolerance in Patients With Heart Failure With Preserved Ejection Fraction. *JAMA Cardiol*. 2023;8:575-584. doi: 10.1001/jamacardio.2023.0957

8. Lena A, Anker MS, Springer J. Muscle Wasting and Sarcopenia in Heart Failure-The Current State of Science. *Int J Mol Sci*. 2020;21. doi: 10.3390/ijms21186549

9. Hahn VS, Selvaraj S, Sharma K, Shah SH. Towards metabolomic-based precision approaches for classifying and treating heart failure. *Basic to Translational Science*. 2024;9:1144-1158.

10. Hage C, Löfgren L, Michopoulos F, Davidsson P, Kumar C, Ekström M, Eriksson MJ, Lyngå P, Persson B, Wallén H. Metabolomic profile in HFpEF vs HFrEF patients. *Journal of cardiac failure*. 2020;26:1050-1059.

11. Wang D, Day EA, Townsend LK, Djordjevic D, Jørgensen SB, Steinberg GR. GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease. *Nat Rev Endocrinol*. 2021;17:592-607. doi: 10.1038/s41574-021-00529-7

12. Kamper RS, Nygaard H, Praeger-Jahnsen L, Ekmann A, Ditlev SB, Schultz M, Hansen SK, Hansen P, Pressel E, Suetta C. GDF-15 is associated with sarcopenia and frailty in acutely admitted older medical patients. *J Cachexia Sarcopenia Muscle*. 2024;15:1549-1557. doi: 10.1002/jcsm.13513

13. Bielka W, Przezak A, Pawlik A. Follistatin and follistatin-like 3 in metabolic disorders. *Prostaglandins Other Lipid Mediat*. 2023;169:106785. doi: 10.1016/j.prostaglandins.2023.106785

14. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*. 2021;42:3599-3726. doi: 10.1093/eurheartj/ehab368

15. Hagströmer M, Oja P, Sjöström M. The International Physical Activity Questionnaire (IPAQ): a study of concurrent and construct validity. *Public Health Nutr*. 2006;9:755-762. doi: 10.1079/phn2005898

16. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA. Frailty in older adults:

evidence for a phenotype. *J Gerontol A Biol Sci Med Sci*. 2001;56:M146-156. doi: 10.1093/gerona/56.3.m146

17. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA. Sarcopenia: revised European consensus on definition and diagnosis. *Age and ageing*. 2019;48:16-31.

18. Beaudart C, Biver E, Reginster J-Y, Rizzoli R, Rolland Y, Bautmans I, Petermans J, Gillain S, Buckinx F, Van Beveren J. Development of a self-administrated quality of life questionnaire for sarcopenia in elderly subjects: the SarQoL. *Age and ageing*. 2015;44:960-966.

19. Malmstrom TK, Morley JE. SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. *Journal of the American Medical Directors Association*. 2013;14:531-532.

20. Guigoz Y, Vellas B, Garry PJ. Assessing the nutritional status of the elderly: The Mini Nutritional Assessment as part of the geriatric evaluation. *Nutrition reviews*. 1996;54:S59-S65.

21. Buysse DJ, Reynolds CF, 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. *Psychiatry Res*. 1989;28:193-213. doi: 10.1016/0165-1781(89)90047-4

22. Bastien CH, Vallières A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. *Sleep Med*. 2001;2:297-307. doi: 10.1016/s1389-9457(00)00065-4

23. Dunn WB, Wilson ID, Nicholls AW, Broadhurst D. The importance of experimental design and QC samples in large-scale and MS-driven untargeted metabolomic studies of humans. *Bioanalysis*. 2012;4:2249-2264. doi: 10.4155/bio.12.204

24. Lopaschuk GD, Karwi QG, Tian R, Wende AR, Abel ED. Cardiac energy metabolism in heart failure. *Circulation research*. 2021;128:1487-1513.

25. Smith GL, Eisner DA. Calcium buffering in the heart in health and disease. *Circulation*. 2019;139:2358-2371.

26. Knowlton AA, Chen L, Malik ZA. Heart failure and mitochondrial dysfunction: the role of mitochondrial fission/fusion abnormalities and new therapeutic strategies. *Journal of cardiovascular pharmacology*. 2014;63:196-206.

27. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, Lewis GD, Fox CS, Jacques PF, Fernandez C. Metabolite profiles and the risk of developing diabetes. *Nature medicine*. 2011;17:448-453.

28. Murashige D, Jang C, Neinast M, Edwards JJ, Cowan A, Hyman MC, Rabinowitz JD, Frankel DS, Arany Z. Comprehensive quantification of fuel use by the failing and nonfailing human heart. *Science*. 2020;370:364-368.

29. Drake KJ, Sidorov VY, McGuinness OP, Wasserman DH, Wikswo JP. Amino acids as metabolic substrates during cardiac ischemia. *Experimental Biology and Medicine*. 2012;237:1369-1378.

30. Hakuno D, Hamba Y, Toya T, Adachi T. Plasma amino acid profiling identifies specific amino acid associations with cardiovascular function in patients with systolic heart failure. *PLoS One*. 2015;10:e0117325.

31. Dhar I, Lysne V, Seifert R, Svingen GF, Ueland PM, Nygård OK. Plasma methionine and risk of acute myocardial infarction: Effect modification by established risk factors. *Atherosclerosis*. 2018;272:175-181.

32. Tran DH, Wang ZV. Glucose metabolism in cardiac hypertrophy and heart failure. *Journal of the American Heart Association*. 2019;8:e012673.

33. Shekarchian A, Bandarian F, Hadizadeh A, Amirsardari Z, Sharifi Y, Ayati A, Varmaghani M, Shandiz AF, Sharifi F, Ghadery AH. Exploring the metabolomics profile of frailty-a systematic review. *Journal of Diabetes & Metabolic Disorders*. 2024;23:289-303.

34. Adachi Y, Ono N, Imaizumi A, Muramatsu T, Andou T, Shimodaira Y, Nagao K, Kageyama Y, Mori M, Noguchi Y. Plasma amino acid profile in severely frail elderly patients in Japan. *International Journal of Gerontology*. 2018;12:290-293.

35. Carbone L, Bůžková P, Robbins JA, Fink HA, Barzilay JI, Elam RE, Isales C. Association of serum levels of phenylalanine and tyrosine with hip fractures and

frailty in older adults: The cardiovascular health study. *Archives of Osteoporosis*. 2024;19:51.

36. Zhou M, Sun W, Chu J, Liao Y, Xu P, Chen X, Li M. Identification of novel biomarkers for frailty diagnosis via serum amino acids metabolomic analysis using UPLC-MS/MS. *PROTEOMICS–Clinical Applications*. 2024;18:2300035.

37. Chen WS, Wang CH, Cheng CW, Liu MH, Chu CM, Wu HP, Huang PC, Lin YT, Ko T, Chen WH. Elevated plasma phenylalanine predicts mortality in critical patients with heart failure. *ESC Heart failure*. 2020;7:2884-2893.

38. Wang C-H, Cheng M-L, Liu M-H, Fu T-C. Amino acid-based metabolic profile provides functional assessment and prognostic value for heart failure outpatients. *Disease Markers*. 2019;2019:8632726.

39. Yang C, Shi Z, Bao L, Xv X, Jiang D, You L. Targeted metabolomic analysis of serum amino acids in heart failure patients. *Amino Acids*. 2024;56:22.

40. Prokopidis K, Ishiguchi H, Jordan C, Irlik K, Nabrdalik K, Formiga F, Sankaranarayanan R, Lip GY, Isanejad M. Association between natriuretic peptides and C-reactive protein with frailty in heart failure: a systematic review and meta-analysis. *Aging clinical and experimental research*. 2024;36:57.

41. Prokopidis K, Nortcliffe A, Okoye C, Venturelli M, Lip GY, Isanejad M. Length of stay and prior heart failure admission in frailty and heart failure: A systematic review and meta-analysis. *ESC Heart Failure*. 2025.

42. Sathyan S, Ayers E, Gao T, Milman S, Barzilai N, Verghese J. Plasma proteomic profile of frailty. *Aging Cell*. 2020;19:e13193.

43. di Candia AM, de Avila DX, Moreira GR, Villacorta H, Maisel AS. Growth differentiation factor-15, a novel systemic biomarker of oxidative stress, inflammation, and cellular aging: Potential role in cardiovascular diseases. *American Heart Journal Plus: Cardiology Research and Practice*. 2021;9:100046.

44. Kamper RS, Nygaard H, Praeger-Jahnsen L, Ekmann A, Ditlev SB, Schultz M, Hansen SK, Hansen P, Pressel E, Suetta C. GDF-15 is associated with sarcopenia and frailty in acutely admitted older medical patients. *Journal of Cachexia, Sarcopenia and Muscle*. 2024;15:1549-1557.

45. Binder MS, Yanek LR, Yang W, Butcher B, Norgard S, Marine JE, Kolandaivelu A, Chrispin J, Fedarko NS, Calkins H. Growth Differentiation Factor-15 Predicts Mortality and Heart Failure Exacerbation But Not Ventricular Arrhythmias in Patients With Cardiomyopathy. *Journal of the American Heart Association*. 2023;12:e8023.

46. Teramoto K, Nochioka K, Sakata Y, Nishimura K, Shimokawa H, Yasuda S, Investigators ST. Prognostic significance of growth differentiation factor-15 across age in chronic heart failure. *ESC heart failure*. 2024;11:1666-1676.

47. Sakamoto D, Matsuoka Y, Nakatani D, Okada K, Sunaga A, Kida H, Sato T, Kitamura T, Tamaki S, Seo M. Role and prognostic value of growth differentiation factor 15 in patient of heart failure with preserved ejection fraction: insights from the PURSUIT-HFpEF registry. *Open Heart*. 2025;12.

48. Yndestad A, Ueland T, Øie E, Florholmen G, Halvorsen B, Attramadal Hv, Simonsen S, Frøland SS, Gullestad L, Christensen G. Elevated levels of activin A in heart failure: potential role in myocardial remodeling. *Circulation*. 2004;109:1379-1385.

49. Oshima Y, Ouchi N, Shimano M, Pimentel DR, Papanicolaou KN, Panse KD, Tsuchida K, Lara-Pezzi E, Lee S-J, Walsh K. Activin A and follistatin-like 3 determine the susceptibility of heart to ischemic injury. *Circulation*. 2009;120:1606-1615.

50. James K, Jamil Y, Kumar M, Kwak MJ, Nanna MG, Qazi S, Troy AL, Butt JH, Damluji AA, Forman DE. Frailty and cardiovascular health. *Journal of the American Heart Association*. 2024;13:e031736.

51. Chen J, Kastroll J, Bello FM, Pangburn MM, Murali A, Smith PM, Rychcik K, Loughridge KE, Vandevender AM, Dedousis N, et al. Skeletal muscle mitochondrial dysfunction is associated with increased Gdf15 expression and circulating GDF15 levels in aged mice. *Sci Rep*. 2025;15:8101. doi: 10.1038/s41598-025-92572-x

52. Chen Y, Wu J. Aging-related sarcopenia: metabolic characteristics and therapeutic strategies. *Aging and Disease*. 2024;16:1003.

53. Migliavacca E, Tay SK, Patel HP, Sonntag T, Civiletto G, McFarlane C, Forrester T, Barton SJ, Leow MK, Antoun E. Mitochondrial oxidative capacity and NAD+ biosynthesis are reduced in human sarcopenia across ethnicities. *Nature communications*. 2019;10:5808.

54. Groarke JD, Crawford J, Collins SM, Lubaczewski S, Roeland EJ, Naito T, Hendifar AE, Fallon M, Takayama K, Asmis T, et al. Ponsegromab for the Treatment of Cancer Cachexia. *N Engl J Med*. 2024;391:2291-2303. doi: 10.1056/NEJMoa2409515

55. Wang Y-C, Koay YC, Pan C, Zhou Z, Tang W, Wilcox J, Li XS, Zagouras A, Marques F, Allayee H, et al. Indole-3-Propionic Acid Protects Against Heart Failure With Preserved Ejection Fraction. *Circulation Research*. 2024;134:371-389. doi: 10.1161/CIRCRESAHA.123.322381

56. Buondonno I, Sassi F, Carignano G, Dutto F, Ferreri C, Pili FG, Massaia M, Nisoli E, Ruocco C, Porrino P. From mitochondria to healthy aging: the role of branched-chain amino acids treatment: MATeR a randomized study. *Clinical Nutrition*. 2020;39:2080-2091.

57. Mishra M, Wu J, Kane AE, Howlett SE. The intersection of frailty and metabolism. *Cell metabolism*. 2024;36:893-911.

58. Liguori I, Curcio F, Russo G, Cellurale M, Aran L, Bulli G, Della-Morte D, Gargiulo G, Testa G, Cacciatore F. Risk of malnutrition evaluated by mini nutritional assessment and sarcopenia in noninstitutionalized elderly people. *Nutrition in Clinical Practice*. 2018;33:879-886.

59. Mirkowski K, Vellone E, Żółkowska B, Jędrzejczyk M, Czapla M, Uchmanowicz I, Uchmanowicz B. Frailty and Heart Failure: Clinical Insights, Patient Outcomes and Future Directions. *Card Fail Rev*. 2025;11:e05. doi: 10.15420/cfr.2024.34

Table 1. Characteristics of the included participants. Data is presented as mean (standard deviation).

	NonHF-NonFrail (n=21)	**NonHF-Frail (n=8)**	**HF-NonFrail (n=7)**	**HF-Frail (n=18)**	***P (among groups)***
Sample (m/f)	21 (11/10)	8 (3/5)	7 (5/2)	18 (14/4)	0.03[a]
Age (years)	68.4 (12.3)	66.5 (8.0)	68.4 (10.7)	67.8 (10.1)	NS
HFpEF/HFrEF	-	-	3/4	14/4	-
NYHA class (I-II/III)	-	-	6/0	14/3	-
Systolic blood pressure (mmHg)	133.1 (13.5)	122.5 (7.3)	131.7 (13.7)	120.1 (18.5)	<0.01[c]
Diastolic blood pressure (mmHg)	80.5 (7.9)	76.8 (7.8)	74.3 (11.6)	70.6 (11.9)	<0.01[c]
Resting heart rate (beats/min)	71.0 (12.9)	73.4 (13.1)	59.6 (19.6)	64.2 (10.5)	0.048[d]
Comorbidities – n (%)					
Type 2 diabetes	-	-	2 (33.3)	5 (29.4)	-
Hypertension			3 (50.0)	10 (58.8)	
Chronic kidney disease			1 (16.7)	6 (35.3)	
Atrial fibrillation			3 (50.0)	5 (29.4)	
Chronic obstructive pulmonary disease			0 (0)	2 (11.8)	
Myocardial infarction			0 (0)	1 (5.9)	
Medications – n (%)					
ACE-I/ARB	-	-	2 (33.3)	8 (47.1)	-
B-blockers			4 (66.7)	15 (88.2)	
Loop diuretics					

MRA SGLT2i			3 (50.0) 0 (0) 3 (50.0)	8 (47.1) 8 (47.1) 10 (58.8)	
Body mass index (kg/m^2)	25.1 (2.8)	26.5 (3.5)	31.3 (6.3)	30.4 (7.0)	<0.01[b], <0.01[c]
Fat mass (kg)	20.83 (4.61)	26.77 (8.28)	33.19 (10.11)	33.33 (14.26)	0.047[e], <0.01[b], <0.01[c]
Fat Free Mass (kg)	49.30 (10.49)	45.34 (6.78)	55.44 (11.20)	56.69 (9.69)	0.02[c], 0.01[a]
Appendicular lean mass (kg)	20.21 (5.48)	18.91 (3.79)	24.00 (6.07)	23.83 (4.43)	0.03[a]
Skeletal Muscle Index (kg/m^2)	7.38 (1.04)	6.91 (1.07)	8.56 (1.61)	8.04 (1.19)	0.01[b], 0.046[c], 0.01[d], 0.03[a]
Appendicular lean soft tissue /BMI	0.30 (0.03)	0.26 (0.03)	0.28 (0.06)	0.27 (0.03)	0.01[e], 0.03[c]
Lean soft tissue (kg)	46.69 (9.91)	42.84 (6.44)	52.52 (10.60)	53.78 (9.35)	0.02[c], 0.01[a]
Body fat (%)	31.0 (4.9)	37.8 (7.8)	41.7 (12.0)	36.9 (8.1)	<0.01[e], <0.01[b], <0.01[c]
VAT (cm^3)	1024.1 (696.9)	1153.1 (691.3)	2413.3 (1847.6)	2503.8 (1400.3)	<0.01[b], <0.01[c], 0.03[a]
VAT (kg)	0.97 (0.66)	1.09 (0.65)	2.28 (1.74)	2.36 (1.32)	<0.01[b], <0.01[c], 0.03[a]
Bone mineral density (g/cm^2)	1.18 (0.17)	1.18 (0.07)	1.23 (0.20)	1.21 (0.12)	NS

Visceral adipose tissue (cm^3)	1024.1 (696.9)	1153.1 (691.3)	2413.3 (1847.6)	2503.8 (1400.3)	<0.01[b], <0.01[c], 0.03[a]
Visceral adipose tissue (kg)	0.97 (0.66)	1.09 (0.65)	2.28 (1.74)	2.36 (1.32)	<0.01[b], <0.01[c], 0.03[a]
6 Minute Walking distance (m)	501.3 (79.7)	480.3 (33.2)	453.5 (53.9)	386.4 (110.4)	<0.01[c], 0.02[d]
Time Up and Go (seconds)	7.36 (1.77)	7.88 (0.84)	8.72 (1.25)	11.61 (4.66)	<0.01[c], <0.01[b], 0.04[f]
30second Chair stand (repetitions)	14.2 (3.1)	11.3 (1.8)	13.9 (0.9)	9.2 (3.1)	<0.01[c], <0.01[f]
Gait Speed (m/s)	1.40 (0.30)	1.26 (0.13)	1.23 (0.22)	1.06 (0.32)	<0.01[c]
Hand Grip Strength (kg)	35.6 (9.4)	30.3 (10.0)	37.0 (12.2)	30.7 (12.0)	NS
Hand grip/BMI	1.41 (0.32)	1.15 (0.36)	1.22 (0.47)	1.05 (0.45)	0.035 [c]
Knee extension strength (kg)	36.5 (16.1)	30.7 (16.0)	32.0 (13.1)	30.3 (14.1)	NS
Sedentary (min/d)	309.4 (144.8)	377.1 (102.3)	285.0 (158.5)	416.0 (151.2)	0.045[c]
Moderate activity (min/week)	60.7 (36.5)	40.0 (36.3)	94.3 (127.8)	17.2 (42.4)	0.02[c], <0.01[f]
Vigorous activity (min/week)	37.2 (25.4)	41.9 (81.9)	42.9 (113.4)	1.1 (4.7)	<0.01[c]
Metabolic equivalent of task score	3306.1 (1970.1)	2442.8 (3481.6)	3531.0 (2752.4)	678.6 (684.0)	<0.01[e], <0.01[c], 0.03[d], <0.01[f]

Mini nutritional assessment score	13.3 (1.2)	12.4 (2.1)	13.0 (1.0)	10.6 (2.3)	<0.01[c], 0.04[a], <0.01[f]
SARC-F	0.3 (0.6)	1.0 (1.4)	1.7 (1.7)	2.9 (3.5)	<0.01[c]
SarQoL	83.7 (10.0)	75.5 (16.6)	65.8 (12.8)	57.9 (17.6)	0.01[b], <0.01[c], <0.01[a]
Pittsburgh sleep quality index	4.9 (2.0)	6.5 (3.9)	9.0 (4.2)	8.7 (4.5)	0.02[b], <0.01[c]
Insomnia severity index	3.6 (3.2)	5.4 (6.7)	7.0 (4.2)	10.8 (8.2)	<0.01[c]
Insulin (pg/mL)	656.0 (807.1)	462.9 (343.1)	287.1 (200.4)	818.9 (1126.0)	NS
Glucose (mg/dL)	85.2 (15.8)	79.6 (10.6)	93.0 (17.3)	111.8 (60.9)	0.01[a] 0.02[d]
HOMA-IR	2.58 (3.87)	1.61 (1.33)	1.22 (1.14)	6.22 (14.90)	<0.01[b]
CRP (mg/dL)	1.92 (2.19)	1.98 (1.26)	2.99 (3.03)	2.85 (2.83)	NS
IL-6 (pg/mL)	65.5 (127.7)	-	3.45 (4.40)	45.2 (128.3)	NS
NT-proBNP (pg/mL)	117.1 (114.2)	111.1 (88.2)	104.1 (25.0)	241.2 (198.0)	0.01[c]
TNF-a (pg/mL)	4.44 (1.63)	4.43 (1.50)	8.45 (7.00)	7.04 (2.24)	0.01[a] 0.007[c]
Follistatin-3 (pg/mL)	10,531.4 (15,288.1)	25,807.4 (56,244.5)	36,712.8 (36,819.8)	33,432.8 (53,446.3)	NS
Activin A (pg/mL)	594.9 (719.4)	486.3 (386.9)	213.4 (161.3)	155.3 (143.4)	0.046[a]
Activin A/ Follistatin-3	0.16	0.15	0,01	0.03	0.037[c]

GDF-15 (pg/mL)	382.5 (236.0)	556.3 (391.8)	456.4 (395.8)	1227.2 (933.2)	<0.01[a] 0.03[c]
Myostatin (ng/mL)	1.15 (0.65)	1.32 (1.59)	1.15 (0.81)	1.45 (1.56)	NS

Table S1. Pairwise comparison for total HF and total NonHF

Metabolites Names	t.stat	p.value	FDR
2-Piperidinecarboxylic acid	-0.13222	0.89535	0.91594
3-(1-pyrazolyl)-L-alanine	0.6112	0.54389	0.66129
3-Methyl-2-oxopentanoic-acid_1	-1.7851	0.08043	0.16343
4-androsten-3,17-dione 2	2.8604	0.0062028	0.020446
Acetic acid. 4-hydroxyphenyl-	-2.5427	0.014209	0.040381
Adipic acid. 2-amino-	-0.9175	0.36337	0.49754
Alanine	-6.4227	5.20E-08	1.05E-06
Arabinoheptulosonic acid enol. 3-deoxy- BP	-1.6061	0.11467	0.21808
Arabitol	-0.91393	0.36523	0.49779
Asparagine	5.2377	3.41E-06	3.30E-05
Aspartic acid	2.4139	0.019563	0.05213
Benzoic acid.	0.76915	0.4455	0.57463
Benzylalcohol	-1.4454	0.1547	0.26997
Beta-D-Allose	0.88558	0.38017	0.51265
Butanoic acid. 2-amino-	1.9287	0.059573	0.12869
Butanoic acid. 2-hydroxy-	-1.4717	0.14751	0.26362
Butanoic acid. 2.4-dihydroxy-	-2.7079	0.0092971	0.027954
Butanoic acid. 3-hydroxy-	-1.8894	0.064759	0.13855
Caffeine	0.65122	0.51795	0.63495
Carbodiimide	0.35244	0.72602	0.79381
Catechol	0.81747	0.41762	0.5482
Citric acid	-1.245	0.21906	0.34691

Creatinine	4.026	0.0001965	0.0012318
Cysteine	4.2244	0.0001038	0.0006996
Cysteine. S-methyl-. DL-	0.54053	0.59128	0.70165
Cysteinyl-glycine	1.8768	0.066506	0.1416
Cystine	-3.239	0.0021561	0.0085668
Cystineamine	-8.1991	9.49E-11	6.04E-09
Decanoic acid	0.60526	0.5478	0.66236
Diethylenglycol	-4.086	0.0001622	0.0010462
dihydrotestosterone	0.75811	0.45202	0.57968
DL- Glutamine	5.0899	5.68E-06	5.06E-05
Dodecanoic acid	-1.3985	0.16826	0.28578
Ergothioneine	-2.776	0.0077721	0.024356
Erythritol	-2.0537	0.045362	0.10299
Erythrose	-0.27924	0.78123	0.83771
Fructose	3.4832	0.001053	0.0047815
Fucose	-2.9401	0.0049955	0.017049
Fumaric acid	-1.2251	0.22639	0.35724
Furan-2-carboxylic acid	2.5417	0.014247	0.040381
Galactonic acid	-1.4835	0.14436	0.26074

Galactonic acid-1.4-lactone	9.6191	7.19E-13	1.07E-10
Galactose	-3.451	0.0011591	0.0051071
Galactose. 2-amino-2-deoxy	-1.1442	0.2581	0.39199
Galactose. 2-deoxy	-3.775	0.0004329	0.002408
Galacturonic acid	-4.0496	0.0001823	0.0011587
Galacturonic acid-1-phosphate	-2.7115	0.0092113	0.027885
Glucoheptonic acid-1.4-lactone	-1.0228	0.31142	0.4514
Gluconic acid-1.4-lactone	4.7595	1.76E-05	0.0001421
Glucopyranose	-1.2771	0.20759	0.33335
Glucose. 2-deoxy	-2.5695	0.013277	0.038313
Glutamic acid	-3.9178	0.0002769	0.0016215
Glutamine	0.3157	0.75357	0.8179
Glutaric acid	-2.0586	0.044868	0.10239
Glutaric acid. 2-hydroxy-	-0.99214	0.32601	0.46163
Glutaric acid. 2-oxo-	-3.6554	0.0006257	0.0032757
Glyceric acid	-1.3353	0.18794	0.3144
Glycerol	-4.1361	0.0001381	0.0009036
Glycine	1.5824	0.12	0.22531

Glycine.1	2.4161	0.01946	0.05213
Glycolic acid	0.16496	0.86965	0.89999
Glyoxylic acid	4.2516	9.50E-05	0.0006502
Heptadecanoic acid	0.56351	0.57566	0.68678
Hippuric acid	-1.7798	0.081311	0.16447
Histidine	6.244	9.83E-08	1.82E-06
Histidine. N-tau-methyl-	1.819	0.07503	0.15498
Hydroquinone	2.1961	0.032846	0.080311
Hypotaurine	-1.0956	0.27861	0.4119
Hypoxanthine	-1.1068	0.27377	0.40609
Idose	-6.1408	1.42E-07	2.49E-06
Indole-3-acetamide	2.0592	0.044808	0.10239
Indole-3-acetic acid	-0.98554	0.3292	0.46359
Indole. 3-hydroxy-	-1.6126	0.11325	0.2163
Isobutanoic acid. 3-amino-	-2.1769	0.034335	0.082589
Isocaproic acid. 2-oxo	-1.1935	0.23842	0.36967
Isoleucine	-3.6082	0.0007224	0.0035719
Isomaltose	-3.2405	0.0021472	0.0085668
isopropyl beta-D-1-thiogalactopyranoside [19.097]	-1.4481	0.15396	0.26973
Isovaleric acid. 2-oxo	-2.4221	0.019174	0.051711

Lactic acid	1.4735	0.147	0.26362
Lactic acid. 3-(4-hydroxyphenyl)-	-0.71011	0.481	0.60126
Loganin	-1.1797	0.24382	0.37543
Lysine	-1.3564	0.18118	0.30425
Malic acid	-3.3366	0.0016244	0.0067558
Malonic acid	-2.3433	0.023214	0.059812
Mannopyranoside	-0.1047	0.91704	0.93169
Methionine	-4.7151	2.04E-05	0.0001565
Methoxytryptamine	-1.6762	0.10007	0.19447
Muramic acid. N-acetyl	3.3849	0.0014096	0.0060443
Myo-Inositol	2.9778	0.0045037	0.015781
N-acetyl Galactosamine	-4.0146	0.0002038	0.0012594
N-acetyl- Aspartic acid	-6.1343	1.45E-07	2.49E-06
N-Carboxyglycine	5.0894	5.69E-06	5.06E-05
N-methyl trans-4-hydroxy-L-proline (2S.4R)-4-hydroxy-1-methyl pyrrolidine-2-carboxylic acid	2.0743	0.043327	0.099899
Neryl acetate	-0.36044	0.72007	0.79119
Neuraminic acid. N-glycolyl	-0.21165	0.83326	0.87453

Nivalenol	3.8609	0.0003312	0.0018655
Nonanoic acid	0.36062	0.71993	0.79119
Norleucine	2.5307	0.014645	0.041246
Norvaline	2.0833	0.042462	0.098415
O-Toluic-acid	0.49413	0.62343	0.72246
Octadecadienoic acid	3.7536	0.0004626	0.0025411
Octadecenoic acid	2.1397	0.037387	0.088969
Octadecenoic acid methyl ester	5.8686	3.73E-07	5.18E-06
Octanoic acid	0.99055	0.32677	0.46163
Ornithine	-3.5228	0.0009352	0.0044275
Oxalic acid	0.22816	0.82047	0.86774
Pantothenic acid	0.82624	0.41267	0.54386
Pentanoic acid. 2-propy	-0.43394	0.66623	0.75409
Phenol	0.15102	0.88058	0.90919
Phenylalanine	-5.4738	1.50E-06	1.75E-05
Phosphoric acid	0.72017	0.47484	0.5969
Phosphoric acid monomethyl ester	3.4603	0.0011273	0.0050164
Proline	-0.62299	0.53618	0.6555
Proline. 4-hydroxy	2.6311	0.011346	0.033886
Propane-1.2-diol	-1.8532	0.069883	0.14718

Psicose	-1.1728	0.24655	0.37772
Pyridine. 2-hydroxy-	2.62	0.011674	0.034634
Pyridine. 3-hydroxy-	3.2295	0.002216	0.0087268
Pyroglutamic acid	0.25627	0.79881	0.85245
Pyruvic acid	-1.7491	0.08653	0.17114
Ribitol	-0.70561	0.48377	0.60289
Ribonic acid	-1.7721	0.0826	0.1657
Ribose	0.76957	0.44525	0.57463
Salicin	-1.6147	0.11279	0.2163
Salicylic acid	-1.5542	0.12658	0.23666
Sarcosine	1.599	0.11625	0.22013
Sarcosineamide	1.0417	0.30268	0.44161
Sedoheptulose. 2.7-anhydro-. beta-	3.5166	0.0009526	0.0044443
Serine	-1.016	0.31463	0.45348
Serine. O-phospho-	0.53243	0.59683	0.70494
Siloxane	1.3056	0.19779	0.32333
similar to Asparagine Derivate	5.579	1.03E-06	1.24E-05
similar to Glycerolaldopyranosid	-1.4291	0.15932	0.276
similar to Pentasiloxane. dodecamethyl	-6.6557	2.27E-08	6.04E-07
Sorbose	-0.308	0.75939	0.82221
Tartaric acid	2.4634	0.017321	0.047579
Tartronic acid	-0.97936	0.33221	0.46635

Tetradecanoic acid	-1.5413	0.12968	0.24145
Threonic acid-1.4-lactone	2.8138	0.0070277	0.022662
Threonine	2.6123	0.011906	0.035086
Tryptophan	3.2624	0.0020156	0.008229
Tyrosine	-1.932	0.059159	0.12842
Tyrosine.1	1.6771	0.099896	0.19447
Unknown01	-0.46443	0.6444	0.73716
Unknown02	3.2058	0.0023723	0.0091796
Unknown03	2.0955	0.041317	0.09677
Unknown04	2.2516	0.028863	0.071755
Unknown05	3.7232	0.000508	0.002757
Unknown06	1.7504	0.086313	0.17114
Unknown07	2.5978	0.012357	0.036177
Unknown08	-5.1502	4.61E-06	4.28E-05
Unknown09	2.8835	0.005827	0.019496
Unknown10	-1.4288	0.1594	0.276
Unknown100	1.2168	0.2295	0.36087
Unknown101	-1.305	0.19797	0.32333
Unknown102	1.1946	0.238	0.36967
Unknown103	-0.02459	0.98048	0.98048
Unknown104	-3.879	0.0003129	0.0018081
Unknown105	-1.2596	0.21377	0.33974

Unknown106	4.3269	7.43E-05	0.0005163
Unknown107	0.13256	0.89509	0.91594
Unknown108	11.063	6.34E-15	1.41E-12
Unknown109	3.1156	0.0030663	0.011564
Unknown11	0.23002	0.81903	0.86774
Unknown110	-5.7164	6.38E-07	8.22E-06
Unknown111	-5.9476	2.82E-07	4.18E-06
Unknown112	-4.9683	8.62E-06	7.38E-05
Unknown113	0.52547	0.60162	0.70648
Unknown114	1.8177	0.075227	0.15498
Unknown115	-5.5799	1.03E-06	1.24E-05
Unknown116	-1.7867	0.080179	0.16343
Unknown117	-2.4251	0.019037	0.051655
Unknown118	0.47536	0.63664	0.73395
Unknown119	2.0846	0.042339	0.098415
Unknown12	6.5705	3.07E-08	6.83E-07
Unknown120	2.786	0.0075686	0.023887
Unknown121	0.93783	0.35293	0.48624
Unknown122	-1.3034	0.19853	0.32333
Unknown123	-4.4262	5.35E-05	0.0003906
Unknown124	-5.353	2.28E-06	2.42E-05
Unknown125	2.2898	0.026375	0.06631

Unknown126	-0.77349	0.44295	0.57463
Unknown127	-2.4727	0.016926	0.046782
Unknown128	0.24141	0.81025	0.86258
Unknown129	-0.29043	0.77271	0.83156
Unknown13	6.3835	5.98E-08	1.16E-06
Unknown130	-0.69044	0.49318	0.61132
Unknown131	-1.0154	0.31489	0.45348
Unknown132	1.5345	0.13134	0.24252
Unknown133	2.3403	0.023387	0.059812
Unknown134	2.0287	0.047936	0.10828
Unknown135	-6.8853	9.99E-09	3.17E-07
Unknown136	5.029	7.00E-06	6.11E-05
Unknown137	2.3449	0.023126	0.059812
Unknown138	0.067417	0.94652	0.95946
Unknown139	0.58763	0.55948	0.66927
Unknown14	1.9589	0.055826	0.12178
Unknown140	6.0674	1.84E-07	2.93E-06
Unknown141	0.83607	0.40717	0.54249
Unknown142	0.91834	0.36294	0.49754
Unknown143	-0.68131	0.49888	0.61667
Unknown144	-1.3257	0.19107	0.31608
Unknown145	0.83011	0.4105	0.54367
Unknown146	-1.9744	0.053987	0.11952

Unknown147	1.1978	0.23677	0.36967
Unknown148	0.027913	0.97784	0.98005
Unknown149	2.8227	0.0068636	0.022294
Unknown15	5.1649	4.38E-06	4.15E-05
Unknown150	0.50591	0.61519	0.71478
Unknown151	-2.3254	0.024234	0.061273
Unknown152	-0.38725	0.70025	0.77712
Unknown153	-0.94837	0.3476	0.48037
Unknown154	-0.14741	0.88341	0.91
Unknown155	-1.3086	0.19677	0.32333
Unknown156	0.22601	0.82213	0.86774
Unknown157	-2.2229	0.030869	0.076314
Unknown158	0.051787	0.95891	0.9672
Unknown159	-1.5104	0.13737	0.25052
Unknown16	-0.33803	0.73678	0.80163
Unknown160	-1.6188	0.11191	0.21559
Unknown161	-0.43033	0.66884	0.75409
Unknown162	-6.03	2.10E-07	3.23E-06
Unknown163	-1.9715	0.054324	0.11967
Unknown164	1.1818	0.243	0.37543
Unknown165	-2.508	0.015504	0.043216
Unknown166	-0.83269	0.40906	0.54338

Unknown167	-5.4381	1.70E-06	1.93E-05
Unknown168	-1.1265	0.26544	0.40003
Unknown169	0.19056	0.84965	0.88547
Unknown17	3.3374	0.0016203	0.0067558
Unknown170	-36.169	5.28E-37	2.35E-34
Unknown171	-1.0101	0.3174	0.45416
Unknown172	1.4868	0.14348	0.2606
Unknown173	1.8312	0.073152	0.15212
Unknown174	1.8549	0.069633	0.14718
Unknown175	1.9949	0.051626	0.11603
Unknown176	-0.74986	0.45692	0.58428
Unknown177	2.8365	0.0066143	0.021642
Unknown178	2.7969	0.0073529	0.02354
Unknown179	-0.67088	0.50545	0.62286
Unknown18	-5.8688	3.73E-07	5.18E-06
Unknown180	-2.0997	0.040928	0.096364
Unknown181	1.111	0.27201	0.40483
Unknown182	0.91007	0.36724	0.49824
Unknown183	1.7703	0.082905	0.1657
Unknown184	1.4082	0.16539	0.28416
Unknown185	3.0227	0.0039781	0.014162
Unknown186	3.9365	0.0002611	0.0015489

Unknown187	-8.8465	1.00E-11	9.89E-10
Unknown188	-3.0775	0.0034129	0.012449
Unknown189	-1.8913	0.064504	0.13855
Unknown19	5.402	1.92E-06	2.14E-05
Unknown190	-4.5492	3.56E-05	0.000264
Unknown191	2.1143	0.039599	0.093731
Unknown192	-4.3891	6.05E-05	0.0004275
Unknown193	2.5675	0.013345	0.038313
Unknown194	1.2956	0.20117	0.32553
Unknown195	-6.5957	2.81E-08	6.58E-07
Unknown196	0.8255	0.41309	0.54386
Unknown197	-0.77905	0.4397	0.57212
Unknown198	0.47036	0.64019	0.73424
Unknown199	-0.66891	0.50669	0.62286
Unknown20	-0.59711	0.55319	0.66532
Unknown200	-7.764	4.39E-10	2.44E-08
Unknown201	0.51637	0.60792	0.71004
Unknown202	3.3381	0.0016171	0.0067558
Unknown203	-0.37034	0.71273	0.78701
Unknown204	-3.0485	0.0037019	0.013393
Unknown205	-1.4694	0.14812	0.26365
Unknown206	-1.2752	0.20825	0.33335

Unknown207	-0.37762	0.70734	0.783
Unknown208	0.73878	0.46356	0.58729
Unknown209	0.43191	0.6677	0.75409
Unknown21	4.1603	0.0001277	0.0008481
Unknown210	2.1792	0.034155	0.082589
Unknown211	-1.3018	0.19908	0.32333
Unknown212	6.7454	1.65E-08	4.88E-07
Unknown213	3.8672	0.0003247	0.0018527
Unknown214	-0.049557	0.96068	0.9672
Unknown215	1.6799	0.099347	0.19447
Unknown216	1.3294	0.18986	0.31525
Unknown217	-1.519	0.13519	0.24758
Unknown218	-0.39821	0.69221	0.77395
Unknown219	0.14456	0.88565	0.91019
Unknown22	-1.9907	0.052101	0.11613
Unknown220	4.6398	2.63E-05	0.0001983
Unknown221	-3.5145	0.0009588	0.0044443
Unknown222	0.20494	0.83847	0.87793

Unknown223	1.9899	0.052193	0.11613
Unknown224	0.53187	0.59722	0.70494
Unknown225	2.9384	0.0050188	0.017049
Unknown226	0.70359	0.48502	0.60289
Unknown227	0.71367	0.47882	0.60021
Unknown228	3.6691	0.0005999	0.0031781
Unknown229	0.2218	0.82539	0.86832
Unknown23	0.28922	0.77363	0.83156
Unknown230	2.9946	0.0042994	0.015184
Unknown231	0.35555	0.72371	0.79322
Unknown232	1.2799	0.20661	0.33311
Unknown233	-0.51115	0.61154	0.7124
Unknown234	0.91285	0.36579	0.49779
Unknown235	0.4312	0.66821	0.75409
Unknown236	-0.5253	0.60174	0.70648
Unknown237	1.7104	0.093517	0.18414
Unknown238	2.2686	0.027734	0.069336
Unknown239	0.97479	0.33445	0.46734
Unknown24	-1.5373	0.13064	0.24223
Unknown240	0.22503	0.82289	0.86774
Unknown241	0.40531	0.68702	0.77008
Unknown242	0.85035	0.39927	0.53516

Unknown243	0.041534	0.96704	0.9714
Unknown244	-1.6652	0.10226	0.19785
Unknown245	-0.88833	0.37871	0.51223
Unknown246	-3.1043	0.0031653	0.011738
Unknown247	-1.402	0.16722	0.28578
Unknown248	-4.846	1.31E-05	0.0001079
Unknown249	3.2932	0.0018435	0.007596
Unknown25	1.8053	0.077173	0.15826
Unknown250	0.95703	0.34325	0.47734
Unknown251	-3.5007	0.0009992	0.0045837
Unknown252	-3.2548	0.0020606	0.0083361
Unknown253	3.6489	0.0006383	0.0032924
Unknown254	5.7126	6.47E-07	8.22E-06
Unknown255	3.0257	0.0039447	0.014156
Unknown256	1.5247	0.13376	0.24597
Unknown257	2.1613	0.03559	0.085148
Unknown258	0.94943	0.34706	0.48037
Unknown259	4.9304	9.82E-06	8.24E-05
Unknown26	-1.4149	0.16342	0.28187

Unknown260	1.1331	0.26268	0.39759
Unknown261	4.7412	1.87E-05	0.0001458
Unknown262	-0.48936	0.62677	0.72445
Unknown263	4.0014	0.0002125	0.0012955
Unknown264	-0.42961	0.66936	0.75409
Unknown265	0.052064	0.95869	0.9672
Unknown266	3.0853	0.0033389	0.01228
Unknown267	0.99656	0.32387	0.46163
Unknown268	2.1921	0.03315	0.080609
Unknown269	-1.3776	0.17458	0.29427
Unknown27	1.3818	0.17329	0.2932
Unknown270	-1.4628	0.14991	0.26578
Unknown271	-1.8516	0.070116	0.14718
Unknown272	0.26458	0.79244	0.84768
Unknown273	3.2122	0.002329	0.0090914
Unknown274	-1.4512	0.1531	0.26928
Unknown275	0.29149	0.77191	0.83156
Unknown276	0.17042	0.86538	0.89766
Unknown277	-1.0117	0.31664	0.45416

Unknown278	-3.4777	0.0010704	0.0048115
Unknown279	2.3302	0.023959	0.060923
Unknown28	-4.4028	5.78E-05	0.0004151
Unknown280	-2.7626	0.0080516	0.025056
Unknown281	-2.7165	0.0090914	0.027885
Unknown282	-1.1716	0.247	0.37772
Unknown283	-5.2399	3.38E-06	3.30E-05
Unknown284	0.11556	0.90848	0.92511
Unknown285	-2.9403	0.0049925	0.017049
Unknown286	-3.1515	0.00277	0.010615
Unknown288	-1.1208	0.26784	0.40003
Unknown289	0.73752	0.46433	0.58729
Unknown29	-0.76647	0.44707	0.57499
Unknown290	6.4466	4.78E-08	1.01E-06
Unknown291	-6.1055	1.61E-07	2.65E-06
Unknown292	8.8157	1.11E-11	9.89E-10
Unknown293	-2.4524	0.0178	0.048595
Unknown294	1.1948	0.23793	0.36967
Unknown295	-2.9344	0.0050731	0.017103
Unknown296	0.41476	0.68013	0.76429
Unknown30	0.38721	0.70028	0.77712
Unknown31	-0.99405	0.32508	0.46163

Unknown32	6.6257	2.52E-08	6.24E-07
Unknown33	-1.9596	0.055746	0.12178
Unknown34	3.6102	0.000718	0.0035719
Unknown35	3.5986	0.0007437	0.003637
Unknown36	1.3986	0.16823	0.28578
Unknown37	-4.7412	1.87E-05	0.0001458
Unknown38	3.5731	0.0008036	0.0038871
Unknown39	-1.7695	0.083034	0.1657
Unknown40	-2.3507	0.022809	0.059705
Unknown41	-2.9678	0.00463	0.016097
Unknown42	-3.6455	0.0006448	0.0032924
Unknown43	-0.59073	0.55742	0.6686
Unknown44	-0.84664	0.40131	0.53629
Unknown45	-0.39419	0.69515	0.7753
Unknown46	8.7543	1.37E-11	1.02E-09
Unknown47	0.34426	0.73213	0.79852
Unknown48	-0.74071	0.4624	0.58729
Unknown49	-1.0289	0.30858	0.44875
Unknown50	-1.0479	0.29983	0.4389
Unknown51	0.12582	0.90039	0.91898

Unknown52	0.61177	0.54352	0.66129
Unknown53	-2.7341	0.0086815	0.026828
Unknown54	1.0615	0.29368	0.43131
Unknown55	3.5228	0.0009352	0.0044275
Unknown56	7.1366	4.08E-09	1.65E-07
Unknown57	0.60308	0.54924	0.66236
Unknown58	-2.7133	0.0091683	0.027885
Unknown59	-3.9562	0.0002453	0.0014754
Unknown60	-1.8333	0.072837	0.15212
Unknown61	-1.4821	0.14472	0.26074
Unknown62	-0.78279	0.43752	0.57096
Unknown63	0.52306	0.60329	0.70648
Unknown64	-3.1085	0.0031279	0.011697
Unknown65	1.1228	0.267	0.40003
Unknown66	0.4578	0.64912	0.74066
Unknown67	-3.1488	0.002791	0.010615
Unknown68	0.6085	0.54567	0.66164
Unknown69	-2.2097	0.03183	0.078257
Unknown70	-1.1566	0.25305	0.38564
Unknown71	6.6508	2.31E-08	6.04E-07
Unknown72	2.3718	0.021672	0.057066
Unknown73	-0.72347	0.47283	0.59606

Unknown74	5.3133	2.62E-06	2.65E-05
Unknown75	1.1207	0.26789	0.40003
Unknown76	1.3298	0.18973	0.31525
Unknown77	2.3945	0.020512	0.054332
Unknown78	0.19771	0.84409	0.88173
Unknown79	-2.3418	0.023298	0.059812
Unknown80	0.73714	0.46455	0.58729
Unknown81	-3.71	0.0005292	0.0028372
Unknown82	-0.97365	0.33501	0.46734
Unknown83	-3.3842	0.0014126	0.0060443
Unknown84	5.3602	2.23E-06	2.42E-05
Unknown85	1.0903	0.2809	0.41392
Unknown86	1.587	0.11894	0.22427
Unknown87	-0.17819	0.8593	0.89344
Unknown88	-0.4704	0.64015	0.73424
Unknown89	6.9199	8.83E-09	3.15E-07
Unknown90	0.85884	0.39461	0.53052
Unknown91	5.3274	2.49E-06	2.58E-05
Unknown92	-3.4393	0.0011999	0.005235
Unknown93	-7.4601	1.29E-09	6.38E-08
Unknown94	5.7562	5.55E-07	7.48E-06
Unknown95	-7.1775	3.52E-09	1.57E-07

Unknown96	-6.9086	9.19E-09	3.15E-07
Unknown97	0.55509	0.58136	0.69172
Unknown98	3.6423	0.0006511	0.0032924
Unknown99	2.787	0.007549	0.023887
Urea	-2.5696	0.013274	0.038313
Uric acid	0.81484	0.41911	0.54854
Valeric acid. 2-oxo-	-2.5071	0.015538	0.043216
Valine	-2.8753	0.0059584	0.019787
Xanthine	-1.4591	0.15091	0.26649
Xylitol	1.27	0.21009	0.33509

Table S2. Mummichog pathway enrichment. Analysis for HF and nonfailing control based on top 10% significant differences.

	Pathway total	Hits.total	Hits.sig	Expected	P(Fisher)	P(EASE)	P(Gamma)
Beta-Alanine metabolism	20	6	3	0.29324	0.086766	0.31427	0.0054081
Urea cycle/amino group metabolism	85	17	5	1.2463	0.20859	0.39963	0.0071995
Lysine metabolism	52	13	4	0.76241	0.22417	0.45481	0.008712
Aspartate and asparagine metabolism	114	28	6	1.6714	0.45946	0.6383	0.017212
Androgen and estrogen biosynthesis and metabolism	95	5	2	1.3929	0.24566	0.6501	0.018043
Fatty Acid Metabolism	63	6	2	0.92369	0.3251	0.71727	0.023867
Valine, leucine and isoleucine degradation	65	7	2	0.95302	0.40248	0.77179	0.030509
C21-steroid hormone biosynthesis and metabolism	112	8	2	1.6421	0.47568	0.81599	0.037888
Glycine, serine, alanine and threonine metabolism	88	11	2	1.2902	0.66049	0.90417	0.063537
N-Glycan biosynthesis	48	1	1	0.70377	0.19214	1	1
Alkaloid biosynthesis II	10	4	1	0.14662	0.57674	1	1
Histidine metabolism	33	4	1	0.48384	0.57674	1	1
Vitamin B5 - CoA biosynthesis from pantothenate	12	2	1	0.17594	0.34804	1	1
Biopterin metabolism	22	3	1	0.32256	0.47441	1	1
Tryptophan metabolism	94	23	1	1.3782	0.99443	1	1
Vitamin A (retinol) metabolism	67	3	1	0.98234	0.47441	1	1
CoA Catabolism	7	3	1	0.10263	0.47441	1	1
Butanoate metabolism	34	6	1	0.4985	0.72639	1	1
Arginine and Proline Metabolism	45	13	1	0.65978	0.94263	1	1
Glutamate metabolism	15	1	1	0.21993	0.19214	1	1
Benzoate degradation via CoA ligation	4	1	1	0.058647	0.19214	1	1
Fatty acid activation	74	3	1	1.085	0.47441	1	1
Pyrimidine metabolism	70	4	1	1.0263	0.57674	1	1
Tyrosine metabolism	160	23	1	2.3459	0.99443	1	1

Table S3. Pairwise comparison for HF-Frail and NonHF-NonFrail			
	t.stat	p.value	FDR
2-Piperidinecarboxylic acid	0.20208	0.84102	0.90182
3-(1-pyrazolyl)-L-alanine	0.452	0.65406	0.76073
3-Methyl-2-oxopentanoic-acid_1	-1.9596	0.058049	0.12185
4-androsten-3,17-dione 2	3.3986	0.0017046	0.0073375
Acetic acid. 4-hydroxyphenyl-	-2.3472	0.024703	0.062815
Adipic acid. 2-amino-	-1.4721	0.14994	0.25701
Alanine	-6.0319	7.01E-07	1.51E-05
Arabinoheptulosonic acid enol. 3-deoxy-BP	-1.3547	0.18421	0.29593
Arabitol	-1.7212	0.094053	0.1804
Asparagine	4.1247	0.00021732	0.0014434
Aspartic acid	0.78625	0.43701	0.56697
Benzoic acid.	1.745	0.089756	0.17366
Benzylalcohol	-1.74	0.090644	0.17462
Beta-D-Allose	0.58262	0.56388	0.69317
Butanoic acid. 2-amino-	1.3722	0.17874	0.29076
Butanoic acid. 2-hydroxy-	-1.2646	0.21437	0.33239

Butanoic acid. 2.4-dihydroxy-	-3.3854	0.0017669	0.0074882
Butanoic acid. 3-hydroxy-	-1.1051	0.27664	0.39712
Caffeine	0.84016	0.40652	0.53572
Carbodiimide	-0.61258	0.54412	0.67259
Catechol	0.19064	0.84991	0.90481
Citric acid	-2.7321	0.0097962	0.030555
Creatinine	3.3098	0.0021713	0.0087839
Cysteine	3.4318	0.0015558	0.0068549
Cysteine. S-methyl-. DL-	0.097944	0.92254	0.9525
Cysteinyl-glycine	1.7511	0.088682	0.17309
Cystine	-3.6283	0.00090118	0.00436
Cystineamine	-7.1566	2.40E-08	1.19E-06
Decanoic acid	0.28247	0.77925	0.8626
Diethylenglycol	-5.0853	1.24E-05	0.00013136
dihydrotestosterone	1.1195	0.27057	0.38966
DL- Glutamine	4.4445	8.48E-05	0.00068606
Dodecanoic acid	-1.2417	0.22259	0.34038
Ergothioneine	-3.3325	0.0020412	0.0083334
Erythritol	-2.6313	0.012564	0.036782

Erythrose	0.42159	0.6759	0.78124
Fructose	2.1921	0.035117	0.082071
Fucose	-3.1015	0.0037925	0.014182
Fumaric acid	-2.7785	0.0087214	0.028123
Furan-2-carboxylic acid	1.4323	0.16092	0.27023
Galactonic acid	-2.9578	0.0055215	0.019347
Galactonic acid-1.4-lactone	8.0723	1.67E-09	2.11E-07
Galactose	-3.9166	0.00039706	0.0023249
Galactose. 2-amino-2-deoxy	-1.4357	0.15998	0.26966
Galactose. 2-deoxy	-4.1633	0.00019416	0.00135
Galacturonic acid	-4.9885	1.66E-05	0.00016066
Galacturonic acid-1-phosphate	-1.9242	0.062497	0.12935
Glucoheptonic acid-1.4-lactone	-1.3722	0.17872	0.29076
Gluconic acid-1.4-lactone	3.8295	0.00050979	0.0029084
Glucopyranose	-1.2448	0.22147	0.34038
Glucose. 2-deoxy	-2.1212	0.041064	0.090462
Glutamic acid	-4.1387	0.00020859	0.0014253
Glutamine	-0.39154	0.69777	0.79414
Glutaric acid	-2.3896	0.022385	0.060014

Glutaric acid. 2-hydroxy-	-1.8318	0.075505	0.14976
Glutaric acid. 2-oxo-	-5.2232	8.17E-06	9.32E-05
Glyceric acid	-2.1276	0.04049	0.089642
Glycerol	-3.5781	0.0010371	0.0049096
Glycine	1.4863	0.14615	0.25306
Glycine.1	2.5875	0.013981	0.040138
Glycolic acid	0.053286	0.95781	0.96879
Glyoxylic acid	3.7523	0.00063506	0.0034048
Heptadecanoic acid	1.2082	0.23509	0.35245
Hippuric acid	-2.2909	0.028106	0.068769
Histidine	5.307	6.33E-06	7.83E-05
Histidine. N-tau-methyl-	1.6573	0.1064	0.19565
Hydroquinone	1.553	0.12943	0.22947
Hypotaurine	-1.6107	0.11624	0.21027
Hypoxanthine	-1.5469	0.13088	0.2302
Idose	-4.9733	1.74E-05	0.00016462
Indole-3-acetamide	2.8668	0.0069753	0.023164
Indole-3-acetic acid	-2.186	0.035595	0.082071
Indole. 3-hydroxy-	-1.2067	0.23565	0.35245

Isobutanoic acid. 3-amino-	-3.2167	0.0027911	0.011008
Isocaproic acid. 2-oxo	-0.83946	0.40691	0.53572
Isoleucine	-3.9309	0.00038106	0.002261
Isomaltose	-3.9777	0.00033298	0.0020298
isopropyl beta-D-1-thiogalactopyranoside [19.097]	-2.0373	0.049234	0.10533
Isovaleric acid. 2-oxo	-2.2275	0.032443	0.077205
Lactic acid	1.1947	0.24023	0.35753
Lactic acid. 3-(4-hydroxyphenyl)-	-0.67357	0.50501	0.63672
Loganin	-2.2906	0.028126	0.068769
Lysine	-1.4131	0.16646	0.27847
Malic acid	-4.4971	7.25E-05	0.00059765
Malonic acid	-1.9016	0.065475	0.13365
Mannopyranoside	-0.1157	0.90855	0.94685
Methionine	-4.3378	0.00011627	0.00090771
Methoxytryptamine	-1.8304	0.075722	0.14976
Muramic acid. N-acetyl	2.9688	0.0053658	0.019102
Myo-Inositol	2.1817	0.035939	0.082437
N-acetyl Galactosamine	-3.7406	0.00065647	0.0034777

N-acetyl- Aspartic acid	-6.0036	7.64E-07	1.51E-05
N-Carboxyglycine	4.3767	0.00010365	0.00082364
N-methyl trans-4-hydroxy-L-proline (2S.4R)-4-hydroxy-1-methyl pyrrolidine-2-carboxylic acid	2.3286	0.025782	0.064332
Neryl acetate	-0.40074	0.69104	0.79267
Neuraminic acid. N-glycolyl	-0.12492	0.9013	0.94685
Nivalenol	3.5493	0.0011237	0.0051553
Nonanoic acid	1.9751	0.056186	0.1185
Norleucine	1.1695	0.25011	0.36976
Norvaline	1.1294	0.26639	0.38614
O-Toluic-acid	0.984	0.33187	0.46295
Octadecadienoic acid	4.0546	0.00026649	0.0017264
Octadecenoic acid	2.0628	0.04661	0.10069
Octadecenoic acid methyl ester	6.2008	4.20E-07	1.17E-05
Octanoic acid	1.4712	0.15017	0.25701
Ornithine	-3.3475	0.00196	0.0082088
Oxalic acid	0.1164	0.908	0.94685
Pantothenic acid	1.0473	0.30212	0.42816

Pentanoic acid. 2-propy	-0.5757	0.5685	0.69693
Phenol	0.13564	0.89288	0.94154
Phenylalanine	-6.7162	8.91E-08	3.30E-06
Phosphoric acid	0.9844	0.33168	0.46295
Phosphoric acid monomethyl ester	3.5914	0.00099922	0.0047812
Proline	-1.3234	0.19429	0.30602
Proline. 4-hydroxy	1.7718	0.08513	0.16762
Propane-1.2-diol	-1.9186	0.063226	0.13026
Psicose	-1.0559	0.29824	0.42537
Pyridine. 2-hydroxy-	1.6771	0.10244	0.19073
Pyridine. 3-hydroxy-	2.1276	0.04049	0.089642
Pyroglutamic acid	0.14262	0.88741	0.938
Pyruvic acid	-3.0805	0.0040081	0.01462
Ribitol	-0.61739	0.54098	0.67057
Ribonic acid	-2.3212	0.026225	0.064834
Ribose	0.020181	0.98401	0.98401
Salicin	-2.7048	0.010485	0.031957
Salicylic acid	-2.1731	0.036628	0.083161
Sarcosine	0.19105	0.84959	0.90481

Sarcosineamide	1.2164	0.23196	0.35168
Sedoheptulose. 2.7-anhydro-. beta-	1.8945	0.06644	0.135
Serine	-0.94264	0.35233	0.48541
Serine. O-phospho-	-0.080284	0.93647	0.9602
Siloxane	1.1419	0.26126	0.38097
similar to Asparagine Derivate	4.3033	0.00012872	0.00098432
similar to Glycerolaldopyranosid	-2.3764	0.023087	0.060169
similar to Pentasiloxane. dodecamethyl	-6.3921	2.36E-07	7.50E-06
Sorbose	-0.71775	0.47767	0.60907
Tartaric acid	1.4625	0.15252	0.25906
Tartronic acid	-1.5622	0.12725	0.22741
Tetradecanoic acid	-1.1556	0.25568	0.3755
Threonic acid-1.4-lactone	2.1461	0.038874	0.087369
Threonine	1.2077	0.23526	0.35245
Tryptophan	2.6927	0.010801	0.032697
Tyrosine	-2.499	0.017296	0.048408
Tyrosine.1	0.35221	0.7268	0.81879
Unknown01	-1.5507	0.12996	0.2295

Unknown02	5.0171	1.52E-05	0.00015068
Unknown03	2.0181	0.051293	0.10921
Unknown04	2.2206	0.032947	0.077987
Unknown05	5.2795	6.88E-06	8.28E-05
Unknown06	2.5662	0.014719	0.041719
Unknown07	2.387	0.022522	0.060014
Unknown08	-5.4883	3.65E-06	4.95E-05
Unknown09	1.5565	0.1286	0.2289
Unknown10	-2.4957	0.017432	0.048439
Unknown100	2.3885	0.022443	0.060014
Unknown101	-0.054361	0.95696	0.96879
Unknown102	1.3823	0.17565	0.29036
Unknown103	-0.05706	0.95482	0.96879
Unknown104	-4.0477	0.00027189	0.0017264
Unknown105	-4.9251	2.01E-05	0.00018263
Unknown106	4.2429	0.00015378	0.0011405
Unknown107	1.062	0.29553	0.42287
Unknown108	9.87	1.19E-11	2.65E-09

Unknown109	2.2749	0.029146	0.070565
Unknown11	-0.26395	0.79337	0.87388
Unknown110	-5.1154	1.13E-05	0.00012283
Unknown111	-5.2414	7.73E-06	9.05E-05
Unknown112	-5.2144	8.39E-06	9.33E-05
Unknown113	1.4599	0.15325	0.2593
Unknown114	0.3789	0.70705	0.80264
Unknown115	-4.9375	1.94E-05	0.0001796
Unknown116	-3.3449	0.0019738	0.0082088
Unknown117	-3.7295	0.00067738	0.0035463
Unknown118	1.1672	0.25102	0.36987
Unknown119	1.3805	0.17617	0.29036
Unknown12	5.8586	1.19E-06	2.03E-05
Unknown120	1.9324	0.061439	0.12776
Unknown121	0.39157	0.69775	0.79414
Unknown122	-0.25517	0.80008	0.87694
Unknown123	-6.1171	5.41E-07	1.27E-05
Unknown124	-5.4281	4.38E-06	5.74E-05
Unknown125	1.6689	0.10406	0.19214

Unknown126	-1.4944	0.14404	0.25038
Unknown127	-2.2531	0.030626	0.073271
Unknown128	0.23855	0.81285	0.88224
Unknown129	-0.93924	0.35405	0.48559
Unknown13	5.7425	1.69E-06	2.59E-05
Unknown130	-0.29944	0.76637	0.85046
Unknown131	-0.8908	0.37912	0.50816
Unknown132	1.4992	0.1428	0.2492
Unknown133	2.3752	0.023149	0.060169
Unknown134	1.8595	0.071376	0.14307
Unknown135	-6.1164	5.43E-07	1.27E-05
Unknown136	4.0086	0.00030454	0.0018822
Unknown137	2.9642	0.0054304	0.019179
Unknown138	-0.62665	0.53495	0.66496
Unknown139	0.32502	0.7471	0.83743
Unknown14	2.3499	0.024544	0.062771
Unknown140	3.9093	0.00040551	0.0023435
Unknown141	1.3192	0.19567	0.30602
Unknown142	0.53988	0.5927	0.71284

Unknown143	-1.05	0.30092	0.42783
Unknown144	-1.216	0.2321	0.35168
Unknown145	-0.1958	0.8459	0.90481
Unknown146	-2.1868	0.035529	0.082071
Unknown147	0.95227	0.34749	0.48172
Unknown148	-0.84114	0.40598	0.53572
Unknown149	2.0852	0.044409	0.0964
Unknown15	3.6478	0.00085315	0.0043142
Unknown150	-0.50342	0.61783	0.73315
Unknown151	-1.5743	0.1244	0.22323
Unknown152	-0.30235	0.76418	0.85015
Unknown153	-2.0114	0.052033	0.11026
Unknown154	-0.88661	0.38134	0.5096
Unknown155	-1.854	0.072186	0.14405
Unknown156	0.31538	0.75435	0.84343
Unknown157	-1.9506	0.059143	0.12356
Unknown158	-0.91038	0.36885	0.50195
Unknown159	-1.5355	0.13364	0.23414
Unknown16	-1.3214	0.19495	0.30602

Unknown160	-2.8472	0.0073319	0.024168
Unknown161	0.16451	0.87027	0.92428
Unknown162	-5.0573	1.35E-05	0.00013963
Unknown163	-1.3241	0.19406	0.30602
Unknown164	0.67345	0.50509	0.63672
Unknown165	-2.383	0.022732	0.060032
Unknown166	-1.3209	0.19509	0.30602
Unknown167	-4.5735	5.78E-05	0.00049434
Unknown168	-3.552	0.0011154	0.0051553
Unknown169	0.024838	0.98032	0.98401
Unknown17	1.6932	0.099292	0.18666
Unknown170	-29.504	2.57E-26	1.15E-23
Unknown171	-1.1533	0.25661	0.37563
Unknown172	1.3754	0.17774	0.29076
Unknown173	2.5672	0.014685	0.041719
Unknown174	2.3336	0.025488	0.06408
Unknown175	2.2084	0.033859	0.079722
Unknown176	-0.8996	0.37448	0.50549
Unknown177	2.2718	0.029356	0.070614

Unknown178	2.2745	0.029177	0.070565
Unknown179	-0.67713	0.50278	0.63672
Unknown18	-6.021	7.24E-07	1.51E-05
Unknown180	-1.6926	0.099413	0.18666
Unknown181	1.7544	0.088111	0.17273
Unknown182	1.484	0.14677	0.25315
Unknown183	1.2435	0.22195	0.34038
Unknown184	0.81647	0.41975	0.54938
Unknown185	2.7311	0.0098188	0.030555
Unknown186	2.739	0.0096275	0.030385
Unknown187	-7.5814	6.90E-09	5.12E-07
Unknown188	-3.1036	0.0037717	0.014182
Unknown189	-2.3516	0.024451	0.062771
Unknown19	3.637	0.00087945	0.0043484
Unknown190	-4.5259	6.66E-05	0.00055884
Unknown191	1.6272	0.11267	0.20549
Unknown192	-3.7741	0.00059695	0.0033205
Unknown193	2.7527	0.0093055	0.029578
Unknown194	1.5985	0.11893	0.21427

Unknown195	-6.2281	3.87E-07	1.15E-05
Unknown196	0.54209	0.59119	0.71284
Unknown197	-0.51128	0.61236	0.72861
Unknown198	0.053159	0.95791	0.96879
Unknown199	-0.35853	0.7221	0.81557
Unknown20	-0.11789	0.90683	0.94685
Unknown200	-7.0249	3.55E-08	1.58E-06
Unknown201	0.11872	0.90618	0.94685
Unknown202	3.6282	0.0009014	0.00436
Unknown203	-0.094267	0.92544	0.95328
Unknown204	-2.3922	0.022253	0.060014
Unknown205	-1.3215	0.19492	0.30602
Unknown206	-1.468	0.15104	0.25751
Unknown207	0.22232	0.82536	0.89364
Unknown208	0.52445	0.60327	0.7236
Unknown209	0.070414	0.94427	0.96376
Unknown21	2.6729	0.011344	0.033654
Unknown210	2.3436	0.024906	0.062973

Unknown211	-1.6298	0.1121	0.20529
Unknown212	8.0286	1.89E-09	2.11E-07
Unknown213	3.7673	0.00060851	0.003343
Unknown214	-0.64238	0.52481	0.65601
Unknown215	4.0432	0.00027545	0.0017264
Unknown216	1.3827	0.17552	0.29036
Unknown217	-1.3712	0.17903	0.29076
Unknown218	-0.78399	0.43832	0.56701
Unknown219	0.23968	0.81197	0.88224
Unknown22	-2.0896	0.043992	0.095964
Unknown220	4.1951	0.00017691	0.0012496
Unknown221	-3.5532	0.0011117	0.0051553
Unknown222	-0.1115	0.91186	0.94808
Unknown223	2.1861	0.035589	0.082071
Unknown224	0.75452	0.45559	0.58258
Unknown225	2.6369	0.012394	0.036526
Unknown226	0.57008	0.57226	0.69769
Unknown227	0.63196	0.53152	0.66254
Unknown228	3.3372	0.0020154	0.008304

Unknown229	-0.10419	0.91761	0.94962
Unknown23	0.8574	0.39706	0.52901
Unknown230	2.9051	0.0063235	0.021646
Unknown231	0.32899	0.74413	0.8362
Unknown232	0.97667	0.33543	0.46646
Unknown233	-0.57034	0.57209	0.69769
Unknown234	0.84441	0.40417	0.53572
Unknown235	0.45104	0.65474	0.76073
Unknown236	-0.5535	0.58344	0.70552
Unknown237	1.2898	0.20559	0.31988
Unknown238	2.0603	0.046865	0.10075
Unknown239	0.67765	0.50245	0.63672
Unknown24	-1.747	0.089417	0.17366
Unknown240	-0.2055	0.83837	0.90115
Unknown241	0.81358	0.42138	0.5499
Unknown242	0.23893	0.81256	0.88224
Unknown243	-0.10608	0.91613	0.94962
Unknown244	-1.3385	0.18938	0.30314
Unknown245	-0.15379	0.87866	0.93096

Unknown246	-2.3732	0.023256	0.060169
Unknown247	-2.7123	0.010291	0.031581
Unknown248	-5.5681	2.87E-06	4.11E-05
Unknown249	3.0175	0.0047278	0.016967
Unknown25	1.122	0.2695	0.38938
Unknown250	0.75803	0.45351	0.58238
Unknown251	-2.8414	0.0074403	0.024345
Unknown252	-3.3964	0.0017148	0.0073375
Unknown253	3.6432	0.00086432	0.0043216
Unknown254	5.0404	1.42E-05	0.00014361
Unknown255	2.6743	0.011306	0.033654
Unknown256	0.26823	0.79009	0.87244
Unknown257	2.3818	0.022799	0.060032
Unknown258	0.89883	0.37489	0.50549
Unknown259	4.7129	3.81E-05	0.00033215
Unknown26	-1.708	0.096488	0.18428
Unknown260	1.36	0.18252	0.29427
Unknown261	4.858	2.46E-05	0.00021913
Unknown262	-0.49218	0.62567	0.74048

Unknown263	2.589	0.01393	0.040138
Unknown264	-0.45476	0.65209	0.76073
Unknown265	-0.66409	0.51099	0.6414
Unknown266	2.4457	0.019627	0.053583
Unknown267	1.2154	0.23234	0.35168
Unknown268	2.1167	0.041469	0.090905
Unknown269	-1.6879	0.10032	0.18757
Unknown27	1.4024	0.1696	0.28267
Unknown270	-1.6959	0.098779	0.18666
Unknown271	-2.128	0.040452	0.089642
Unknown272	-0.40062	0.69113	0.79267
Unknown273	3.0921	0.0038881	0.014418
Unknown274	-2.1755	0.036429	0.083133
Unknown275	0.43673	0.66499	0.77062
Unknown276	-0.20926	0.83546	0.90019
Unknown277	-0.94695	0.35016	0.48391
Unknown278	-3.1947	0.0029607	0.011557
Unknown279	3.5247	0.0012035	0.0054098
Unknown28	-3.0867	0.0039437	0.014504

Unknown280	-3.2162	0.0027952	0.011008
Unknown281	-3.7778	0.00059064	0.0033205
Unknown282	-1.1714	0.24935	0.36976
Unknown283	-5.8324	1.28E-06	2.12E-05
Unknown284	-2.6816	0.011103	0.033384
Unknown285	-4.2332	0.00015817	0.0011539
Unknown286	-3.4036	0.0016812	0.0073344
Unknown288	-0.9943	0.3269	0.4589
Unknown289	0.51903	0.607	0.72612
Unknown29	-1.2057	0.23602	0.35245
Unknown290	5.9596	8.73E-07	1.62E-05
Unknown291	-5.6034	2.57E-06	3.82E-05
Unknown292	6.9162	4.90E-08	1.98E-06
Unknown293	-2.8327	0.0076058	0.024705
Unknown294	0.085101	0.93267	0.95851
Unknown295	-1.8922	0.06676	0.13504
Unknown296	-1.2571	0.21704	0.33536
Unknown30	-0.45496	0.65194	0.76073
Unknown31	-0.78926	0.43527	0.56636

Unknown32	5.9318	9.50E-07	1.69E-05
Unknown33	-0.90502	0.37164	0.50421
Unknown34	2.4935	0.017525	0.048439
Unknown35	3.6674	0.00080735	0.0041295
Unknown36	0.663	0.51168	0.6414
Unknown37	-4.2986	0.0001305	0.00098432
Unknown38	2.8769	0.0067969	0.022914
Unknown39	-2.154	0.038206	0.086302
Unknown40	-2.9092	0.0062585	0.021589
Unknown41	-4.2082	0.00017022	0.0012218
Unknown42	-3.1407	0.003419	0.013004
Unknown43	-0.56538	0.57543	0.69963
Unknown44	-1.7016	0.097695	0.18579
Unknown45	7.3878	1.22E-08	7.73E-07
Unknown46	7.2025	2.10E-08	1.17E-06
Unknown47	-0.25537	0.79993	0.87694
Unknown48	-0.91136	0.36834	0.50195
Unknown49	-0.77959	0.44087	0.56866
Unknown50	-1.6189	0.11444	0.20786

Unknown51	0.30778	0.76007	0.8477
Unknown52	0.51448	0.61015	0.72793
Unknown53	-2.484	0.017928	0.049246
Unknown54	1.3182	0.19599	0.30602
Unknown55	2.8731	0.0068633	0.022964
Unknown56	6.1476	4.94E-07	1.27E-05
Unknown57	0.48056	0.63382	0.74814
Unknown58	-2.6072	0.013328	0.038763
Unknown59	-3.4336	0.0015484	0.0068549
Unknown60	-1.9052	0.065001	0.1333
Unknown61	-1.1401	0.26197	0.38097
Unknown62	-0.37295	0.71143	0.80557
Unknown63	0.40729	0.68628	0.79118
Unknown64	-3.5253	0.0012015	0.0054098
Unknown65	1.6729	0.10326	0.19146
Unknown66	-0.25185	0.80263	0.87757
Unknown67	-3.7077	0.00072053	0.0037283
Unknown68	0.044447	0.9648	0.97355
Unknown69	-2.762	0.0090905	0.029103

Unknown70	-1.3671	0.1803	0.29176
Unknown71	5.4868	3.67E-06	4.95E-05
Unknown72	2.5552	0.015115	0.04257
Unknown73	-0.60758	0.54739	0.67476
Unknown74	4.1342	0.0002114	0.0014253
Unknown75	0.81963	0.41797	0.54867
Unknown76	0.89672	0.376	0.50549
Unknown77	2.327	0.025877	0.064332
Unknown78	0.071523	0.94339	0.96376
Unknown79	-3.0555	0.0042812	0.015489
Unknown80	0.39367	0.69621	0.79414
Unknown81	-3.2896	0.0022932	0.0091935
Unknown82	-0.45167	0.65429	0.76073
Unknown83	-2.7158	0.010202	0.031526
Unknown84	3.954	0.00035653	0.002144
Unknown85	1.0068	0.32095	0.45196
Unknown86	0.75699	0.45412	0.58238
Unknown87	0.46718	0.64327	0.75728
Unknown88	0.025196	0.98004	0.98401

Unknown89	5.4042	4.71E-06	5.99E-05
Unknown90	-0.021737	0.98278	0.98401
Unknown91	4.0522	0.00026834	0.0017264
Unknown92	-3.7554	0.00062946	0.0034048
Unknown93	-6.527	1.57E-07	5.38E-06
Unknown94	7.6322	5.95E-09	5.12E-07
Unknown95	-5.9959	7.82E-07	1.51E-05
Unknown96	-5.7774	1.52E-06	2.41E-05
Unknown97	0.93805	0.35465	0.48559
Unknown98	3.1608	0.0032409	0.012433
Unknown99	2.9376	0.0058177	0.020225
Urea	-2.891	0.0065564	0.022272
Uric acid	0.56116	0.57827	0.70117
Valeric acid. 2-oxo-	-1.8791	0.068584	0.1381
Valine	-3.1706	0.0031572	0.012217
Xanthine	-1.0189	0.31524	0.44534
Xylitol	0.21841	0.82838	0.89473

Table S4. Pairwise comparison of metabolites between HF-Frail and HF without physical frailty.

	t.stat	p.value
2-aminobutanoic acid	0.99611	0.33003
2-Furoic acid	-1.4479	0.16175
2-hydroxybutanoic acid	-0.39019	0.70015
2-Piperidinecarboxamide	1.8522	0.077464
2-Piperidinecarboxamide.1	0.16374	0.87143
2-PIPERIDINECARBOXYLIC ACID	1.1341	0.26895
2,4-Dihydroxybutanoic acid	-1.5287	0.14059
3-Hydroxybutyric acid	0.73574	0.46966
3-Methyl-2-oxovaleric acid	-0.007728	0.9939
4-hydroxyphenylacetic acid	-0.83871	0.41065
Adipic acid. 2-amino	-0.51611	0.61093
Alanine	0.99656	0.32982
alanine	0.80597	0.42889
Androstenedione	1.5945	0.12509
Arabinoheptulosonic acid enol. 3-deoxy	-0.41149	0.68469
Arabitol	-0.41703	0.6807

Asparagine	0.040459	0.96809
Asparagine Derivate	-0.25254	0.80297
Aspartic acid	-1.3914	0.17801
Benzoic acid	0.43704	0.66635
Benzylalcohol	0.037945	0.97007
beta-D-allose	-0.065828	0.94811
Caffeine	0.3881	0.70167
Capric Acid	-0.74364	0.46497
Carbodiimides	0.29984	0.76711
Catechol	-0.11679	0.90809
Citric acid	0.57705	0.56976
Creatinine	-0.92904	0.36295
Cystamine	1.7483	0.094359
Cysteine	-0.088923	0.92995
Cysteinylglycine	-1.2369	0.22915
Cystine	1.4154	0.17096
D-Erythrose	1.3017	0.20649
Diethylene glycol	0.56872	0.57531
dihydrotestosterone1	1.6607	0.11096

dihydrotestosterone2	0.28053	0.78169
Ergothioneine	0.57494	0.57117
Erythritol	1.4686	0.15611
Fructose	-1.2135	0.2378
Fructose.1	-1.8759	0.073997
Fucose	1.0781	0.29265
Fumaric acid	-0.96761	0.34376
Galactonic acid	-1.0963	0.28479
Galactonic acid 1,4-lactone, tetra	0.37377	0.71215
Galactose	-0.57536	0.57089
Galactose. 2-amino-2-deoxy	-0.5379	0.59605
Galactose. 2-deoxy	-1.9706	0.061479
Galacturonic acid	-1.1967	0.24415
Galacturonic acid-1-phosphate	2.2455	0.035112
GalNAc-ol	-0.21093	0.83488
Glucoheptonic Acid	1.1571	0.25965
Gluconic acid-1.4-lactone	-0.1075	0.91536
Glucopyranose	0.035276	0.97218
Glucose. 2-deoxy	-0.10617	0.91641

Glutamic acid	2.1517	0.042662
Glutamic acid.1	-2.4197	0.024247
Glutamine	-0.80483	0.42953
Glutaric acid	-0.24897	0.80569
Glutaric acid. 2-hydroxy	-1.9239	0.067402
Glutaric acid. 2-oxo	-1.0249	0.31655
Glyceric acid	-0.82577	0.4178
Glycerol	-0.40809	0.68715
Glycerolaldopyranosid	-1.1968	0.24414
Glycine	0.6596	0.51636
Glycolic acid	-0.10546	0.91697
Glyoxylic acid	0.82138	0.42024
Heptadecanoic acid	0.93641	0.35923
Hexadecenoic acid	-0.27792	0.78367
Hippuric acid	0.099853	0.92137
Histidine	0.82678	0.41724
Histidine. N-tau-methyl	1.0338	0.31245
Hydroquinone	0.58768	0.56273
Hypotaurine	0.17589	0.86199

Hypoxanthine	0.26989	0.78976
Idose	-1.2439	0.22664
Indole-3-acetamide	2.4189	0.024286
Indole-3-acetic acid	-1.7817	0.088604
Indole. 3-hydroxy	0.40212	0.69148
Isobutanoic acid. 3-amino	0.32395	0.74904
Isocaproic acid. 2-oxo	1.4156	0.17091
Isoleucine	2.0093	0.056934
ISOMALTOSE	0.97221	0.34151
Isopropyl beta-D-1-thiogalactopyranoside	-0.57187	0.57321
Isovaleric acid. 2-oxo	-0.054438	0.95708
Lactic acid	0.38206	0.70608
Lactic acid. 3-(4-hydroxyphenyl)	1.0374	0.31083
Lauric Acid	-0.96535	0.34486
Loganin	-0.66621	0.5122
Lysine	0.056955	0.9551
Malic acid	-1.4282	0.16727
Malonic acid	0.46054	0.64965
Mannopyranoside. 1-O-methyl-. Alpha	-1.3326	0.19629

Methionine	2.1372	0.04395
Methoxytryptamine	-0.099062	0.92199
Methylcysteine	1.2425	0.22712
Muramic acid	0.066766	0.94737
Myo-Inositol	-0.070684	0.94429
N-Acetyl-L-Aspartic Acid	1.5696	0.13078
N-Carboxyglycine	-0.59358	0.55885
N-methyl trans-4-hydroxy-L-proline (2S.4R)-4-hydroxy-1-methyl pyrrolidine-2-carboxylic acid	0.16825	0.86792
Neryl acetate	-0.29397	0.77154
Neuraminic acid. N-glycolyl	0.93197	0.36147
Nivalenol	-2.5684	0.01753
Nonanoic acid	1.4203	0.16954
Norleucine	0.012032	0.99051
Norvaline.	0.27491	0.78595
O-Toluic-acid	-0.44504	0.66064
Octadecadienoic acid	-0.14112	0.88906
Octadecenoic acid	-1.0656	0.29818
Octadecenoic acid methyl ester	1.666	0.10989

Octanoic acid	0.25479	0.80125
Ornithine	1.2768	0.21497
Oxalic acid	0.18167	0.8575
Pantothenic acid (Vitamin B5)	0.92877	0.36309
Pentanoic acid. 2-propyl	-0.57126	0.57361
Pentasiloxane. dodecamethyl	0.60514	0.55128
Phenol	0.13196	0.89622
Phenylalanine	0.029728	0.97655
Phosphoric acid	-0.18571	0.85437
Phosphoric acid monomethyl ester	0.42724	0.67335
Proline	-1.3213	0.19998
Proline. 4-hydroxy	-1.4588	0.15876
Propane-1.2-diol	-1.3549	0.18921
Psicose	-0.10467	0.91759
Pyridine. 2-hydroxy	0.58856	0.56215
Pyridine. 3-hydroxy	-0.12134	0.90452
Pyroglutamic acid	1.8787	0.073604
Pyruvic acid	-1.6338	0.11653
Ribitol	-1.4681	0.15624

Ribonic acid	-0.36333	0.71983
Ribose	-1.8532	0.077315
Salicin	-1.1043	0.28138
Salicylic acid	-1.602	0.12342
Sarcosine	-1.0151	0.32111
Sarcosineamide	1.3246	0.1989
Sedoheptulose. 2.7-anhydro- beta	-1.1072	0.28016
Serine	-0.81295	0.42496
Serine. O-phospho	-0.405	0.68939
Siloxane	0.44922	0.65766
Sorbose	0.25203	0.80336
Tartaric acid	-0.39712	0.69511
Tartronic acid	0.3896	0.70058
Tetradecanoic acid	-0.70966	0.48537
Threonic acid-1.4-lactone	0.85214	0.40332
Threonine	-0.045723	0.96394
Tryptophan	1.7734	0.090013
Tyrosine	1.1093	0.27928
Urea	1.3975	0.17621

Uric acid	0.55115	0.58708
Valeric acid. 2-oxo	0.69342	0.4953
Valine	1.7642	0.091576
Xanthine	1.593	0.12542
Xylitol	-1.3358	0.19526
Unknown.1	-1.3424	0.19317
Unknown.10	0.048818	0.96151
Unknown.11	0.10175	0.91987
Unknown.12	0.050166	0.96044
Unknown.13	-0.84001	0.40994
Unknown.14	0.48051	0.63561
Unknown.2	1.386	0.17962
Unknown.3	1.1791	0.25096
Unknown.4	0.30408	0.76392
Unknown.5	0.57577	0.57062
Unknown.6	-1.2702	0.21728
Unknown.7	-0.49066	0.62853
Unknown.8	1.2521	0.22368
Unknown.9	-0.15068	0.8816

Unknown#bth-pae-001	0.69126	0.49664
Unknown#bth-pae-010	-0.19255	0.84907
Unknown#bth-pae-011	1.6932	0.10452
Unknown#bth-pae-038	1.3415	0.19344
Unknown#sst-cgl-010a	0.75037	0.46098
Unknown#sst-cgl-D05	-2.3253	0.029672
Unknown01	0.24059	0.8121
Unknown02	0.56694	0.57649
Unknown03	-0.39206	0.69878
Unknown04	-0.053871	0.95752
Unknown05	-0.58743	0.5629
Unknown06	-1.391	0.17813
Unknown07	0.50951	0.61547
Unknown08	-1.0261	0.31601
Unknown09	-0.098192	0.92267
Unknown10	1.5518	0.13498
Unknown100	0.17977	0.85898
Unknown101	1.5114	0.14492
Unknown102	-0.44207	0.66275

Unknown103	0.56359	0.57873
Unknown104	0.21844	0.8291
Unknown105	-2.7186	0.012544
Unknown106	1.3681	0.18508
Unknown107	-0.86624	0.39571
Unknown108	-1.6858	0.10597
Unknown109	0.79611	0.43448
Unknown11	0.077122	0.93922
Unknown110	-0.52588	0.60423
Unknown111	0.72065	0.47871
Unknown112	1.1968	0.24413
Unknown113	0.63041	0.53492
Unknown114	0.71413	0.48265
Unknown115	-0.28247	0.78022
Unknown116	1.1828	0.24953
Unknown117	-0.83434	0.41306
Unknown118	-0.65563	0.51886
Unknown119	-2.4821	0.021177
Unknown12	0.026926	0.97876

Unknown120	0.33088	0.74387
Unknown121	-0.70581	0.48772
Unknown122	0.017498	0.9862
Unknown123	0.44917	0.6577
Unknown124	-1.392	0.17782
Unknown125	-0.50612	0.61781
Unknown126	1.539	0.13807
Unknown127	1.1259	0.27232
Unknown128	0.92426	0.36538
Unknown129	-1.4751	0.15435
Unknown13	-0.42786	0.67291
Unknown130	0.55923	0.58165
Unknown131	0.15893	0.87518
Unknown132	-0.4551	0.65349
Unknown133	-0.91235	0.37147
Unknown134	-0.42781	0.67295
Unknown135	-0.45346	0.65466
Unknown136	-1.1931	0.24554
Unknown137	-1.103	0.28196

Unknown138	0.21415	0.8324
Unknown139	-0.73305	0.47126
Unknown14	-0.04422	0.96513
Unknown140	0.56361	0.57872
Unknown141	2.3675	0.027124
Unknown142	1.7792	0.089028
Unknown143	-0.86851	0.39449
Unknown144	-1.1536	0.26104
Unknown145	1.3812	0.18107
Unknown146	0.33437	0.74126
Unknown147	-1.9675	0.061859
Unknown148	0.28825	0.77585
Unknown149	0.77235	0.44813
Unknown15	-0.49421	0.62606
Unknown150	1.1289	0.27109
Unknown151	0.27124	0.78874
Unknown152	0.080337	0.9367
Unknown153	0.28014	0.78198
Unknown154	0.5413	0.59374

Unknown155	-0.47928	0.63647
Unknown156	-1.1602	0.25838
Unknown157	-1.166	0.25611
Unknown158	-0.18342	0.85615
Unknown159	-0.53756	0.59628
Unknown16	0.41446	0.68255
Unknown160	1.4579	0.15899
Unknown161	1.373	0.1836
Unknown162	-0.92701	0.36398
Unknown163	-0.86931	0.39406
Unknown164	-0.43017	0.67125
Unknown165	-0.7407	0.46671
Unknown166	-0.33022	0.74436
Unknown167	-1.1698	0.25459
Unknown168	-1.1576	0.25944
Unknown169	-0.41417	0.68276
Unknown17	0.45403	0.65426
Unknown170	-0.64152	0.52781
Unknown171	0.1284	0.899

Unknown172	2.0324	0.054359
Unknown173	0.026301	0.97925
Unknown174	0.44405	0.66135
Unknown175	0.32921	0.74511
Unknown176	0.26998	0.7897
Unknown177	-1.4245	0.16832
Unknown178	1.2767	0.21502
Unknown179	1.735	0.096735
Unknown18	-1.6043	0.12292
Unknown180	-0.16026	0.87414
Unknown181	0.16506	0.8704
Unknown182	0.6512	0.52166
Unknown183	0.0012328	0.99903
Unknown184	0.018276	0.98558
Unknown185	-0.74904	0.46177
Unknown186	1.0209	0.3184
Unknown187	0.90877	0.37332
Unknown188	-0.25154	0.80373
Unknown189	2.1939	0.039098

Unknown19	-1.6206	0.11935
Unknown190	-1.2658	0.21884
Unknown191	0.68034	0.50338
Unknown192	0.98873	0.33355
Unknown193	0.36933	0.71541
Unknown194	-1.8453	0.078505
Unknown195	0.75304	0.45941
Unknown196	-0.54979	0.588
Unknown197	-1.458	0.15897
Unknown198	0.41831	0.67977
Unknown199	0.46667	0.64532
Unknown20	-2.3935	0.025649
Unknown200	2.022	0.055505
Unknown201	-0.0427	0.96633
Unknown202	1.7712	0.090382
Unknown203	0.52323	0.60604
Unknown204	0.72349	0.477
Unknown205	0.34519	0.73323
Unknown206	0.084208	0.93365

Unknown207	1.6359	0.11608
Unknown208	-1.1747	0.25268
Unknown209	0.77685	0.44552
Unknown21	-0.47247	0.64124
Unknown210	0.40399	0.69012
Unknown211	0.30075	0.76643
Unknown212	0.71735	0.48071
Unknown213	-0.55856	0.5821
Unknown214	1.2048	0.24108
Unknown215	-0.22221	0.8262
Unknown216	-0.23652	0.81522
Unknown217	-0.90647	0.37451
Unknown218	0.60478	0.55151
Unknown219	0.24146	0.81143
Unknown22	-0.82946	0.41575
Unknown220	1.0535	0.30353
Unknown221	-0.59217	0.55977
Unknown222	-0.90123	0.37723
Unknown223	-1.7495	0.094136

Unknown224	0.33447	0.74119
Unknown225	1.0447	0.30752
Unknown226	-1.5312	0.13998
Unknown227	-0.062354	0.95084
Unknown228	-0.11307	0.911
Unknown229	-1.2737	0.21606
Unknown23	-2.3326	0.029216
Unknown230	0.72827	0.47413
Unknown231	0.19821	0.8447
Unknown232	1.0466	0.30667
Unknown233	-0.7384	0.46807
Unknown234	0.35419	0.72657
Unknown235	-1.4349	0.16538
Unknown236	-2.0513	0.052334
Unknown237	0.36737	0.71685
Unknown238	0.77122	0.44878
Unknown239	1.3648	0.18612
Unknown24	-1.2838	0.21258
Unknown240	0.81054	0.42631

Unknown241	1.2182	0.23606
Unknown242	-0.37137	0.71392
Unknown243	1.1432	0.26525
Unknown244	-0.33318	0.74215
Unknown245	-1.3424	0.19317
Unknown246	1.386	0.17962
Unknown247	1.1791	0.25096
Unknown248	0.30408	0.76392
Unknown249	0.57577	0.57062
Unknown25	-1.5455	0.13649
Unknown250	-1.2702	0.21728
Unknown251	-0.49066	0.62853
Unknown252	1.2521	0.22368
Unknown253	-0.15068	0.8816
Unknown254	0.048818	0.96151
Unknown255	0.10175	0.91987
Unknown256	0.050166	0.96044
Unknown257	-0.84001	0.40994
Unknown258	0.48051	0.63561

Unknown259	0.69126	0.49664
Unknown26	-0.71626	0.48137
Unknown260	-0.19255	0.84907
Unknown261	1.6932	0.10452
Unknown262	1.3415	0.19344
Unknown263	0.75037	0.46098
Unknown264	-2.3253	0.029672
Unknown27	-1.3264	0.19833
Unknown28	0.001263	0.999
Unknown29	0.71803	0.4803
Unknown30	0.64689	0.5244
Unknown31	0.47201	0.64157
Unknown32	-0.030875	0.97565
Unknown33	0.66071	0.51566
Unknown34	-1.0087	0.32409
Unknown35	0.98109	0.33722
Unknown36	-0.38948	0.70067
Unknown37	0.86803	0.39475
Unknown38	1.3598	0.18768

Unknown39	-0.20432	0.83998
Unknown40	0.46523	0.64634
Unknown41	-0.12473	0.90187
Unknown42	0.75123	0.46047
Unknown43	1.3007	0.20682
Unknown44	0.70804	0.48635
Unknown45	-0.9052	0.37516
Unknown46	0.90495	0.3753
Unknown47	-0.97566	0.33984
Unknown48	0.10278	0.91907
Unknown49	-0.15166	0.88084
Unknown50	1.3789	0.18178
Unknown51	1.8789	0.073576
Unknown52	0.049398	0.96105
Unknown53	0.86758	0.39499
Unknown54	1.3608	0.18735
Unknown55	-1.0138	0.32172
Unknown56	0.65991	0.51616
Unknown57	-0.28358	0.77938

Unknown58	-0.44889	0.6579
Unknown59	-0.12831	0.89907
Unknown60	1.217	0.2365
Unknown61	2.1562	0.042262
Unknown62	-0.74691	0.46302
Unknown63	-1.5984	0.12421
Unknown64	-0.16883	0.86747
Unknown65	-1.3321	0.19647
Unknown66	-0.74747	0.4627
Unknown67	0.68049	0.50329
Unknown68	-0.0094582	0.99254
Unknown69	-1.0242	0.31686
Unknown70	-0.62644	0.53747
Unknown71	-1.0632	0.29924
Unknown72	1.5359	0.13883
Unknown73	-0.074302	0.94144
Unknown74	1.8019	0.085288
Unknown75	1.5843	0.1274

Unknown76	0.77248	0.44805
Unknown77	0.64668	0.52453
Unknown78	0.96614	0.34448
Unknown79	2.4053	0.02501
Unknown80	2.0509	0.052371
Unknown81	1.1049	0.28114
Unknown82	1.6836	0.10639
Unknown83	-0.79518	0.43501
Unknown84	0.40287	0.69093
Unknown85	-0.095625	0.92468
Unknown86	0.91523	0.36999
Unknown87	-1.1623	0.25757
Unknown88	-0.31327	0.75702
Unknown89	0.80356	0.43025
Unknown90	0.80304	0.43054
Unknown91	0.1674	0.86859
Unknown92	1.1439	0.26497
Unknown93	-0.7587	0.45608
Unknown94	1.9815	0.060165

Unknown95	-1.4119	0.17198
Unknown96	-0.12794	0.89936
Unknown97	0.088433	0.93033
Unknown98	0.79155	0.43707
Unknown99	-1.4686	0.15609



Figure 1. Plasma metabolomic signatures in HF and nonfailing control. **A**, PCA analysis shows distinct clusters for HF compared to nonfailing control [F-value: 44.636; R-squared: 0.4767; p-value (based on 999 permutations): 0.001], **B**, and substantial overlap between HFrEF and HFpEF. **C**, Hierarchical clustering of participants (columns) using the plasma metabolome demonstrates similar separation of the HF group from nonfailing control. **D**, Mummichog Pathway Activity Profile for HF compared to non-failing control based on top 10% peaks.



Figure 2. Score plots of partial least squares discriminant analysis (PLS-DA) performed on gas chromatography–mass spectrometry data of plasma samples collected from HF-Frail and HF-NonFrail



Figure 3. Biomarker levels are displayed as the geometric mean with a corresponding 95% CI of the X shows the mean. A) Displays the differences in plasma GDF-15 (growth differentiation factor-15) observing higher levels in HF-frail vs. HF-Not frail (P= 0.02), and NonHF-Frail (P<0.01), and NonHF-Not frail (P=0.03). B) HF-Frail had higher level of TNF-a compared to NonHF-NonFrail (P=0.007) and NonHF-Frail (P=0.01). C) NonHF-Not frail displayed lower NT-proBNP levels (117.1 (114.2) pg/mL) than HF-Frail (241.2 (198.0) pg/mL; P=0.01). D) HF-Frail had higher lowest level of Activin A/ Follistatin-3 (P=0.037) compared to other groups.